Treatment of recurrent glioblastoma with perillyl alcohol
Patent Information
- Application Number
- JP2023528136
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-12
- Filing Date
- 2021-11-12
- Publication Date
- 2024-11-11
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for malignant gliomas, such as glioblastoma, are ineffective due to the difficulty in delivering sufficient chemotherapeutic agents across the blood-brain barrier, leading to poor prognosis and limited efficacy of existing therapies.
Development of a highly purified (S)-perillyl alcohol with a purity greater than 98.5% for direct intranasal delivery, bypassing the blood-brain barrier and combined with chemotherapeutic agents like temozolomide or dimethyl-celecoxib, to treat CNS cancers.
The purified (S)-perillyl alcohol effectively targets CNS tumors with minimal side effects, enhancing treatment efficacy and providing a 50% progression-free survival rate at 6 months, and can be administered through various routes including intranasal, oral, and transdermal delivery.
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 112,799, filed November 12, 2020, the disclosure of which is incorporated herein by reference in its entirety.
[0002] FIELD OF THE INVENTION The present invention relates to monoterpene or sesquiterpene compositions. In particular, the present invention relates to the use of monoterpenes (e.g., (S)-perillyl alcohol) or sesquiterpenes having a purity of greater than about 98.5% (w / w) for treating nervous system tumors. [Background technology]
[0003] Malignant gliomas are the most common form of central nervous system (CNS) cancer and are currently considered essentially incurable. Among various malignant gliomas, anaplastic astrocytoma (grade III) and glioblastoma multiforme (GBM; grade IV) have particularly poor prognoses due to their aggressive growth and resistance to currently available therapies. The current standard of care for malignant gliomas consists of surgery, ionizing radiation, and chemotherapy. Despite recent advances in medicine, the prognosis of malignant gliomas has not improved significantly over the past 50 years. (Wen et al., Malignant gliomas in adults. New England J Med. 359:492-507, 2008; Stupp et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England J Med. 352:987-996, 2005)
[0004] The main reason for the poor prognosis of malignant glioma is the difficulty in delivering sufficient amounts of chemotherapy drugs to the brain. Drug access to the brain is limited by the blood-brain barrier (BBB). The concentration of drugs that ultimately reach the brain is further reduced by hepatic first-pass metabolism and urinary excretion. Therefore, invasive procedures such as tumor resection, stereotactic injection of antitumor drugs, or placement of catheters for convection-enhanced delivery of medications are often required.
[0005] Intranasal drug delivery offers a novel, noninvasive therapy that bypasses the blood-brain barrier and rapidly delivers pharmaceutical agents directly to the CNS. Intranasally administered drugs reach the brain parenchyma, spinal cord, and / or cerebrospinal fluid (CSF) within minutes. In addition to delivery via the olfactory pathway and trigeminal nerve, animal studies suggest that therapeutic agents may also be delivered systemically via the nasal vasculature. See Hashizume et al., "New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163," Neuro-oncology 10:112-120, 2008; Thorne et al., "Delivery of insulin-like growth factor-1 to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration," Neuroscience 127:481-496, 2004. Intranasal delivery of therapeutic agents may provide a systemic approach to treating other types of cancer, such as lung, prostate, breast, hematopoietic, and ovarian cancers.
[0006] The naturally occurring monoterpene perillyl alcohol (POH) has been suggested as an effective agent against various cancers, including CNS, breast, pancreatic, lung, melanoma, and colon cancer. Gould, M. Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect. 1997 June;105(Suppl 4):977-979. Oral perillyl alcohol has been used in a recent Phase I trial sponsored by the National Cancer Institute. Although oral perillyl alcohol did not induce serious side effects, it was generally poorly tolerated, primarily due to gastrointestinal side effects. Its anticancer efficacy was also limited. As a result, its use was discontinued. Ripple et al., Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clinical Cancer Res 6:390-6, 2000.
[0007] To minimize the gastrointestinal side effects of oral POH and provide a means of delivering POH directly to the central nervous system, a nasal formulation of POH for direct intranasal delivery of POH to malignant brain tumors (see below) was investigated by Dr. Clovis Fonseca of Fluminese University in Brazil. Da Fonseca et al., Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review, Surgical Neurology (2006) 66:611-615. This formulation of commercial-grade POH combined with a solvent cocktail has already been administered to 150 patients with recurrent malignant gliomas, showing minimal side effects and a 50% progression-free survival rate at 6 months. Da Fonseca et al., Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Invest New Drugs 2009, Jan. 13.
[0008] Commercial-grade perillyl alcohol, with purity ranging from 85% to 96%, is typically purified from natural sources or by synthetically modifying natural sources such as beta-pinene (extracted from pine trees). Perillyl alcohol obtained through these routes is inevitably contaminated with its isomers and other impurities, which have similar physicochemical properties and are therefore extremely difficult to remove from perillyl alcohol by conventional purification methods such as fractional distillation or chromatography. Perillyl alcohol isomers and other impurities may interfere with the desired therapeutic properties of perillyl alcohol.
[0009] Therefore, there is still a need to produce highly purified perillyl alcohol and use this substance to treat CNS cancers, such as malignant gliomas, and other aggressive brain tumors.Purified perillyl alcohol can be administered alone or in combination with other treatments, including radiation therapy, standard chemotherapy, and surgery.Administration can also be carried out by various routes, including intranasal, oral, pulmonary delivery, and transdermal. Summary of the Invention
[0010] Overview of the invention The present invention provides a method for purifying (S)-perillyl alcohol, comprising the steps of: (a) derivatizing a mixture containing (S)-perillyl alcohol to produce a perillyl alcohol derivative, wherein the perillyl alcohol derivative has at least one property that allows it to be separated from the mixture; (b) separating the perillyl alcohol derivative from the mixture using the property for separation; (c) liberating (S)-perillyl alcohol from the perillyl alcohol derivative from step (b); and (d) isolating the (S)-perillyl alcohol from step (c). The (S)-perillyl alcohol has a purity of greater than about 98.5% (w / w), greater than about 99.0% (w / w), or greater than about 99.5% (w / w). In certain embodiments, the mixture further contains natural product-derived or other impurities. The property of the perillyl alcohol derivative can be the ability to form crystals, and therefore, separation in step (b) can be by crystallization. Separation in step (b) can be by chromatography. The perillyl alcohol derivative can be a perillyl alcohol ester. In one embodiment, the perillyl alcohol ester is a benzoate ester, such as 3,5-dinitrobenzoate.
[0011] The present invention also includes (S)-perillyl alcohol, wherein the (S)-perillyl alcohol has a purity of greater than about 98.5% (w / w), a purity of greater than about 99.0% (w / w), or a purity of greater than about 99.5% (w / w).
[0012] The present invention further provides a pharmaceutical composition comprising (S)-perillyl alcohol having a purity greater than about 98.5% (w / w). The (S)-perillyl alcohol may have a purity greater than about 98.5% (w / w). The pharmaceutical composition may comprise from about 0.1% (w / w) to about 100% (w / w) (S)-perillyl alcohol. The pharmaceutical composition may also comprise a chemotherapeutic agent and at least one pharmaceutically acceptable excipient. The chemotherapeutic agent may be a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducer, a platinum compound, an antimetabolite, an enzyme inhibitor, a receptor antagonist, a therapeutic antibody, or a vaccine. In certain embodiments, the chemotherapeutic agent is dimethyl-celecoxib (DMC), irinotecan (CPT-11), temozolomide, or rolipram. The pharmaceutical composition can be administered alone or before, during, or after radiation therapy or before, during, or after the administration of a chemotherapeutic agent. Routes of administration include inhalation, intranasal, oral, intravenous, subcutaneous, and intramuscular injection. Pharmaceutical compositions may be administered intranasally via an intranasal spray device, atomizer, nebulizer, metered dose inhaler (MDI), pressurized dose inhaler, insufflator, intranasal inhaler, nasal spray bottle, unit dose container, pump, dropper, squeeze bottle, or two-way device. Pharmaceutical compositions may be administered intranasally in the form of a gel, ointment, nasal emulsion, lotion, cream, nasal tampon, or bioadhesive strip.
[0013] The present invention further provides a method for treating cancer, comprising delivering a therapeutically effective amount of (S)-perillyl alcohol having a purity greater than about 98.5% (w / w) to a mammal. The (S)-perillyl alcohol may be mixed or co-formulated with a therapeutic agent, such as a chemotherapeutic agent. The cancer may be a tumor of the nervous system, such as glioblastoma, or other tumor.
[0014] The present invention provides an article of manufacture (e.g., a kit) comprising (S)-perillyl alcohol formulated for intranasal administration and a device for intranasal administration of (S)-perillyl alcohol, wherein the (S)-perillyl alcohol has a purity of greater than about 98.5% (w / w). The device can be an intranasal spray device, an atomizer, a nebulizer, a metered-dose inhaler (MDI), a pressurized-dose inhaler, an insufflator, an intranasal inhaler, a nasal spray bottle, a unit-dose container, a pump, a dropper, a squeeze bottle, or a two-way device. The article of manufacture can further include printed material indicating that (S)-perillyl alcohol is used to treat cancer, such as glioblastoma. The printed material can further indicate that (S)-perillyl alcohol is administered alone or in combination with radiation, surgery, or a chemotherapy agent.
[0015] Also provided is a method for inhibiting cell proliferation (growth), comprising contacting the cells with an effective amount of (S)-perillyl alcohol having a purity greater than about 98.5% (w / w). The contacting can occur in vitro or in vivo. The cells can be glioma cells, meningioma cells, pituitary adenoma cells, lung cancer cells, prostate cancer cells, breast cancer cells, hematopoietic cancer cells, melanoma cells, or ovarian cancer cells. The cells can be temozolomide-resistant cells or cancer stem cells.
[0016] The compositions and methods of the present invention can be used to reduce or inhibit angiogenesis. The compositions and methods of the present invention can reduce or inhibit the production of pro-angiogenic cytokines, including, but not limited to, vascular endothelial growth factor (VEGF) and interleukin 8 (IL8).
[0017] The compositions and methods of the invention can be used to increase paracellular permeability, for example, the paracellular permeability of endothelial or epithelial cells. The compositions and methods of the invention can be used to increase the permeability of the blood-brain barrier.
[0018] The method also includes treating tumors of the nervous system in patients with a mutated isocitrate dehydrogenase 1 (IDH1) gene, the method comprising administering to the patient a pharmaceutical composition containing perillyl alcohol (POH) purified according to the method of the present invention, or administering perillyl alcohol carbamate (wherein the perillyl alcohol carbamate is perillyl alcohol covalently attached to a therapeutic agent, such as temozolamide, rolipram, or dimethylcelecoxib, via a carbamate linking group). The tumor of the central nervous system can be glioblastoma or recurrent glioblastoma. This treatment can be combined with another therapeutic agent, such as a chemotherapeutic agent. [Brief explanation of the drawings]
[0019] [Figure 1] Figure 1: Progression-free survival in different cohorts. Progression-free survival (PFS-6) of patients within the first 6 months after initiation of NEO100 treatment is shown divided into four cohorts containing n=3 patients each. [Figure 2] Figures 2A-2B: Examples of radiographic responses. (Figure 2A) MRI scans of patient 202 before and after 10 months of NEO100 treatment show a partial response. (Figure 2B) MRI scans of patient 301 before and after 12 months of NEO100 treatment show a lack of recurrence during NEO100 treatment. [Figure 3]Figures 3A-3C: Overall survival. (Figure 3A) Survival rates for all patients (n=12) within the first 24 months after initiation of NEO100 treatment are shown, without reference to the number of treatment cycles completed. Overall survival rates at 12 months (OS-12) and 24 months (OS-24) are shown. Median OS is shown at 15 months. Note that one patient (identification number 401) was censored at 4 months (indicated by tick marks) due to loss to follow-up. (Figure 3B) Patient survival rates within the first 24 months after initiation of NEO100 treatment are shown, categorized into patients who completed at least 6 cycles (n=4; indicated as >5 cycles) and those who completed fewer than 5 cycles (n=7; <5 cycles). Patient 401 was not included in this comparison because he was lost to follow-up due to progressive disease after completing 4 cycles. (Figure 3C) Patient survival within the first 24 months after initiation of NEO100 treatment is shown, stratified by IDH1 status in tumor tissue. Four of five patients (80%) with mutant IDH1 survived at least 24 months. Six patients with wild-type IDH1 died of their disease by 18 months. P = .018 (log-rank test). Patient 401 (IDH1 wild-type ("WT or wt")) was censored at s (indicated by tick mark). [Figure 4] Figure 4: Perillic acid concentrations in patient plasma. Perillic acid concentrations were measured in the plasma of all patients (patient identification numbers are shown in the boxes on each graph). Blood was drawn at various time points after completion of NEO100 inhalation: Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 2 Day 1. The boxes on the right show the C-max means for each cohort for each of these three measurements. Each mean was derived from three patients, with one missing data set from patient 401. [Figure 5] Figure 5: Overall survival after NEO100 administration - months from start of NEO100 treatment.
[0020] Detailed description of the invention Abbreviations: cGMP: Current Good Manufacturing Practice; CNS: Central Nervous System; GBM: Glioblastoma (formerly known as glioblastoma multiforme); IDH1: Isocitrate dehydrogenase 1; OS: Overall Survival; MGMT: O6-Methylguanine-DNA methyltransferase; PFS: Progression-Free Survival; WHO: World Health Organization; NEO100 - perillyl alcohol purified according to the methods and materials described herein and in U.S. Patent Nos. 8,500,773, 9,133,085, 9,480,659, 9,498,448, 9,700,524, and 10,4757,618, which are incorporated by reference in their entireties; NEO100 is (S)-perillyl alcohol purified by said methods and is greater than about 99.0% (w / w). IDH1: isocitrate dehydrogenase 1; POH is referred to as perillyl alcohol, also referred to as p-meta-1,7-dien-6-ol; U.S. patents describing perillyl alcohol conjugates are U.S. Patents Nos. 8,916,545, 9,499,461, 9,580,372, 9,663,428, and 10,092,562, which are incorporated by reference in their entireties; IDH1; mut. - mutant; WT or wt is wild type.
[0021] The present invention provides a method for purifying perillyl alcohol from its isomers (including enantiomers) and other impurities typically associated with perillyl alcohol when produced from natural and / or synthetic sources. In purifying perillyl alcohol, perillyl alcohol can be derivatized to produce a crystalline derivative, such as its 3,5-dinitrobenzoate ester. The perillyl alcohol derivative can then be separated from its accompanying contaminants (whether or not they are also present as derivatives) by a suitable technique, such as conventional crystallization or preparative chromatography. The purified perillyl alcohol derivative can then be converted to perillyl alcohol having a purity greater than about 98.5% (w / w). The purified perillyl alcohol can be administered alone to a subject or co-administered with other substances. For example, purified perillyl alcohol can be used to sensitize cancer patients to radiation or chemotherapy. Compared to commercially available (S)-perillyl alcohol, the purified (S)-perillyl alcohol exhibits disproportionately enhanced activity in cellular assays and other therapeutic testing models.
[0022] The present invention provides a method for producing a purified form of a monoterpene or sesquiterpene or monoterpene derivative. The monoterpene (or sesquiterpene) is purified by the following steps: (a) derivatizing a mixture containing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, where the monoterpene (or sesquiterpene) derivative has at least one property that allows it to be separated from the mixture; (b) separating the monoterpene (or sesquiterpene) derivative from the mixture using the property for separation; (c) liberating the monoterpene (or sesquiterpene) from the monoterpene (or sesquiterpene) derivative from step (b); and (d) isolating the monoterpene (or sesquiterpene) from step (c). The purified monoterpene (or sesquiterpene) can have a purity of greater than about 98.5% (w / w), about 99.0% (w / w), or about 99.5% (w / w). In certain embodiments, the mixture further comprises natural product-derived or other impurities. The (S)-perillyl alcohol has a purity of greater than about 98.5% (w / w), greater than about 99.0% (w / w), or greater than about 99.5% (w / w).
[0023] The characteristic of monoterpenes (or sesquiterpenes) can be that they form crystals, and therefore, the separation in step (b) can be by crystallization. The monoterpenes (or sesquiterpenes) are purified by the following steps: (a) derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative; (b) crystallizing the monoterpene (or sesquiterpene) derivative; (c) isolating the monoterpene (or sesquiterpene) derivative crystals of step (b); (d) converting the separated monoterpene (or sesquiterpene) derivative into a monoterpene (or sesquiterpene); and (e) isolating the monoterpene (or sesquiterpene).
[0024] Separation of monoterpenes (or sesquiterpenes) from a mixture can also be by other suitable separation techniques known in the art, such as, but not limited to, chromatography, adsorption, centrifugation, decantation, distillation, electrophoresis, evaporation, extraction, flotation, filtration, sedimentation, and settling. Wikipedia—Separation Process, retrieved February 11, 2010, from URL: http: / / en.wikipedia.org / wiki / Separation_of_mixtures. A property of a monoterpene (or sesquiterpene) derivative useful for separating the derivative from a mixture can be any of its physicochemical properties that differ from those of the other components in the mixture. Physicochemical properties include, but are not limited to, solubility, polarity, partition coefficient, affinity, size, hydrodynamic diameter, and charge. A monoterpene (or sesquiterpene) derivative can be prepared if it has at least one property that differs from that of its isomers, structural variants, or contaminants (those present in the starting material). The chromatography can be any suitable preparative chromatography, including, but not limited to, gas chromatography (GC), high pressure liquid chromatography (HPLC), affinity chromatography, ion exchange chromatography, size exclusion chromatography, and reverse phase chromatography.
[0025] In one embodiment, the monoterpene can be (S)-perillyl alcohol, and the derivatization reaction can include esterification. For example, (S)-perillyl alcohol can be produced using 3,5-dinitrobenzoic acid ester derivatives.
[0026] The present invention further provides monoterpene (or sesquiterpene) compositions having a purity of greater than about 98.5% (w / w), greater than about 99.0% (w / w), or greater than about 99.5% (w / w).
[0027] The purified monoterpene (or sesquiterpene) can be formulated into a pharmaceutical composition, wherein the monoterpene (or sesquiterpene) is present in an amount ranging from about 0.01% (w / w) to about 100% (w / w), about 0.1% (w / w) to about 80% (w / w), about 1% (w / w) to about 70% (w / w), about 10% (w / w) to about 60% (w / w), or about 0.1% (w / w) to about 20% (w / w). The pharmaceutical composition can also contain a therapeutic agent, such as a chemotherapeutic agent. The therapeutic agent can be dissolved in perillyl alcohol. The compositions of the present invention can be administered alone or co-administered with radiation or another agent (e.g., a chemotherapeutic agent) to treat a disease, such as cancer. Treatment can be sequential, with the monoterpene (or sesquiterpene) being administered before or after the administration of the other agent. Alternatively, the substances may be administered simultaneously. The routes of administration may vary and may include inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.
[0028] The present invention also provides a method for treating a disease, such as cancer, comprising delivering to a patient a therapeutically effective amount of a purified monoterpene (or sesquiterpene) produced by the method of the present invention.
[0029] The compositions of the present invention may contain one or more types of monoterpenes (or sesquiterpenes). Monoterpenes include those consisting of two isoprene units and having the molecular formula C 10 H 16The monoterpenes may be linear (acyclic) or may contain a ring. Monoterpenoids produced by biochemical modification, such as oxidation or rearrangement of monoterpenes, and pharmaceutically acceptable salts of monoterpenes or monoterpenoids are also included in the present invention. Examples of monoterpenes and monoterpenoids include perillyl alcohol (S(-)) and R(+)), geranyl pyrophosphate, ocimene, myrcene, geraniol, citral, citronellol, citronellal, linalool, pinene, terpineol, terpinene, limonene, terpinene, phellandrene, terpinolene, terpinen-4-ol (or tea tree oil), pinene, terpineol, terpinene; terpenoids such as p-cymene derived from monocyclic terpenes such as menthol, thymol, and carboxol; and bicyclic monoterpenoids such as camphor, borneol, and eucalyptol.
[0030] Monoterpenes can be distinguished by the structure of their carbon skeleton and can be classified into acyclic monoterpenes (e.g., myrcene, (Z)- and (E)-ocimene, linalool, geraniol, nerol, citronellol, myrcenol, geranial, citral a, neral, citral b, citronellal, etc.), monocyclic monoterpenes (e.g., limonene, terpinene, phellandrene, terpinolene, menthol, carveol, etc.), bicyclic monoterpenes (e.g., pinene, myrtenol, myrtenal, verbanol, verbanone, pinocarveol, carene, sabinene, camphene, thujene, etc.), and tricyclic monoterpenes (e.g., tricyclene). See Encyclopedia of Chemical Technology, Fourth Edition, Volume 23, pp. 834-835.
[0031] The sesquiterpenes of the present invention have the molecular formula C 15 H 24Sesquiterpenes can be linear (acyclic) or can contain a ring. Sesquiterpenoids produced by biochemical modifications, such as oxidation or rearrangement of sesquiterpenes, are also included in the present invention. Examples of sesquiterpenes include farnesol, farnesal, farnesylic acid, and nerolidol.
[0032] A purified monoterpene (or sesquiterpene) can be produced using a derivatized monoterpene (or sesquiterpene), which can be separated from its accompanying contaminants (e.g., its isomers) by crystallization. Crystallization and purification can also increase the chiral purity of the monoterpene (or sesquiterpene).
[0033] Derivatives of monoterpenes (or sesquiterpenes) include, but are not limited to, esters, alcohols, aldehydes, and ketones of monoterpenes (or sesquiterpenes). Monoterpene (or sesquiterpene) alcohols can be derivatized to esters, aldehydes, or acids. Monoterpene (or sesquiterpene) derivatives can be used to regenerate monoterpenes (or sesquiterpenes) by chemical reactions known to those skilled in the art. For example, esters of monoterpenes (or sesquiterpenes) can be hydrolyzed to obtain monoterpenes (or sesquiterpenes).
[0034] In one embodiment, the monoterpene (or sesquiterpene) is purified using an ester of the monoterpene (or sesquiterpene). The purification process can include the following steps: (a) derivatizing the monoterpene (or sesquiterpene) to produce an ester of the monoterpene (or sesquiterpene); (b) crystallizing the ester of the monoterpene (or sesquiterpene); (c) isolating the crystals of the ester of the monoterpene (or sesquiterpene) from step (b); (d) converting the ester of the monoterpene (or sesquiterpene) to the monoterpene (or sesquiterpene); and (e) isolating the monoterpene (or sesquiterpene).
[0035] The esters of monoterpene (or sesquiterpene) alcohols of the present invention can be derived from inorganic or organic acids. Inorganic acids include, but are not limited to, phosphoric acid, sulfuric acid, and nitric acid. Organic acids include, but are not limited to, carboxylic acids such as benzoic acid, fatty acids, acetic acid, and propionic acid. Examples of esters of monoterpene (or sesquiterpene) alcohols include, but are not limited to, carboxylic acid esters (e.g., benzoic acid esters, fatty acid esters (e.g., palmitic acid esters and linoleic acid esters), acetate esters, propionate esters (or propanoic acid esters), and formates), phosphates, sulfates, and carbamates (e.g., N,N-dimethylaminocarbonyl). Wikipedia - Ester; Retrieved from URL: http: / / en.wikipedia.org / wiki / Ester(11 / 11 / 2021).
[0036] In one embodiment, the derivative is a benzoate ester, such as, but not limited to, 3,5-dinitrobenzoate, 4-nitrobenzoate, 3-nitrobenzoate, 4-chlorobenzoate, 3,4,5-trimethoxybenzoate, and 4-methoxybenzoate, an ester of hydroxybenzoic acid, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, hexyl, heptyl, and benzyl ester. (See, e.g., Wikipedia—Benzoate ester http: / / commons.wikimedia.org / wiki / Category:Benzoate_esters).
[0037] A specific example of a monoterpene that can be used in the present invention is perillyl alcohol (commonly abbreviated as POH). The perillyl alcohol composition of the present invention can contain (S)-perillyl alcohol, (R)-perillyl alcohol, or a mixture of (S)-perillyl alcohol and (R)-perillyl alcohol.
[0038] Perillyl alcohol can be purified by the following steps: (a) derivatizing a mixture containing perillyl alcohol to produce a perillyl alcohol derivative, wherein the perillyl alcohol derivative has at least one property that allows it to be separated from the mixture; (b) separating the perillyl alcohol derivative from the mixture using said property for separation; (c) liberating perillyl alcohol from the perillyl alcohol derivative from step (b); and (d) isolating the perillyl alcohol from step (c). In certain embodiments, the mixture further contains natural product-derived or other impurities.
[0039] Perillyl alcohol can be purified using the methods of the present invention using perillyl alcohol derivatives. Derivatives include perillyl alcohol esters, dihydroperillic acid, and perillic acid. Derivatives of perillyl alcohol can also include its oxidation derivatives and nucleophilic / electrophilic addition derivatives. See U.S. Patent Publication No. 20090031455, U.S. Patent Nos. 6,133,324, and 3,957,856. Numerous examples of perillyl alcohol derivatives have been reported in the chemical literature (CAS Scifinder search output file; retrieved January 25, 2010).
[0040] In a specific example, perillyl alcohol is purified by the following steps: (a) derivatizing perillyl alcohol to produce a perillyl alcohol ester; (b) crystallizing the perillyl alcohol ester; (c) separating the perillyl alcohol ester crystals from step (b) (e.g., from the mother liquor); (d) converting the separated perillyl alcohol ester into perillyl alcohol; and (e) isolating the perillyl alcohol. The perillyl alcohol derivative can be used to regenerate perillyl alcohol by chemical reactions known to those skilled in the art. For example, perillyl alcohol can be obtained by hydrolyzing an ester of perillyl alcohol, such as 3,5-dinitrobenzoic acid ester.
[0041] In certain embodiments, esters or ethers of perillyl alcohol can be prepared by reacting perillyl alcohol with an acid chloride or alkyl chloride, the chemical structures of which are shown below. [ka]
[0042] For the esterification reaction, the molar ratio of perillyl alcohol to acid chloride (or alkyl chloride) can be in the range of about 1:1 to about 1:2, about 1:1 to about 1:1.5, for example, about 1:1.05, about 1:1.1, about 1:1.2, about 1:1.3, or about 1:1.4. Suitable reaction solvents include, but are not limited to, dichloromethane, diethyl ether, diisopropyl ether, and methyl t-butyl ether. The reaction can be carried out at a temperature ranging from about −5° C. to about 50° C., or from about −5° C. to 25° C. Suitable bases that can be included in the reaction include, but are not limited to, organic bases such as triethylamine, diisopropylamine, N,N′-diisopropylethylamine, butylamine, sodium methoxide, potassium methoxide, and potassium t-butoxide. The esters obtained in this way include 3,5-dinitrobenzoate, 4-nitrobenzoate, 3-nitrobenzoate, 4-chlorobenzoate, 3,4,5-trimethoxybenzoate, 4-methoxybenzoate, and triphenylmethyl ester. Details of the chemical reactions are given in the examples below.
[0043] Crystallizable monoterpene (or sesquiterpene) derivatives can be purified by crystallization or preparative chromatography. Crystallization separates a product, often in a highly pure form, from a liquid feed stream by cooling the feed stream or by adding a precipitant that reduces the solubility of the desired product to form crystals. For crystallization to occur, the solution must be supersaturated. This means that the solution must contain more dissolved solute than it would at equilibrium (a saturated solution). This can be achieved by a variety of methods, including: 1) cooling the solution; 2) adding a second solvent to reduce the solubility of the solute (a technique known as antisolvent or drown-out); 3) chemical reaction; and 4) changing the pH. Solvent evaporation, spherical crystallization, fractional crystallization, fractional freezing, and other suitable methods can also be used. Mersmann, A. Crystallization Technology Handbook. Edition 2 (2001), published by CRC Press; Myerson et al., Crystallization As a Separations Process (ACS Symposium Series) (1990), published by the American Chemical Society.
[0044] In a specific example, crystallization of 3,5-dinitrobenzoate ester of perillyl alcohol is carried out as follows: The aqueous layer containing the 3,5-dinitrobenzoate ester is extracted with dichloromethane and washed with water. The organic layer containing the 3,5-dinitrobenzoate ester is dried over sodium sulfate. The organic layer is then filtered and concentrated. The resulting residue is finally crystallized from diisopropyl ether mother liquor. The mother liquor is the liquid portion above the crystalline solid and can therefore be separated from the crystals. Separation of the crystals from the mother liquor can be carried out using any suitable technique, including, but not limited to, filtration (with or without the aid of pressure and / or vacuum), centrifugation, and decantation.
[0045] Suitable solvents for crystallization of the benzoate ester of perillyl alcohol include, but are not limited to, ketone solvents (e.g., acetone, methyl ethyl ketone, methyl isobutyl ketone, n-butanone, and t-butyl ketone); nitrile solvents (e.g., acetonitrile and propionitrile); halogenated solvents (e.g., dichloromethane, 1,2-dichloroethane, and chloroform); esters (e.g., ethyl acetate, n-propyl acetate, isopropyl acetate, and t-butyl acetate); ethers (e.g., diethyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, and 1,4-dioxane); hydrocarbon solvents (e.g., hexane, cyclohexane, toluene, and xylene); and mixtures thereof. In one embodiment, the solvent contains methyl t-butyl ether. Dissolution of the benzoate ester in methyl t-butyl ether (7-10 volumes) can be carried out at elevated temperatures, if necessary, to obtain the desired concentration. Further, activated carbon treatment may be performed to remove colored impurities, reduce the content of heavy metals, if present, or remove foreign matter from a solution containing the benzoate ester. Crystallization from the resulting reaction mixture may be carried out by cooling the reaction mixture to a low temperature of about 25°C to about 0°C. Isolation of the crystals may be carried out by removing the solvent and then cooling the reaction mixture. The solvent may be removed by any suitable technique, including evaporation using a rotary evaporator, such as a Buchi rotavapor, under vacuum. The crystals may be isolated from the reaction mixture by any conventional technique, such as gravity filtration or suction filtration. In one embodiment, the benzoate ester may be isolated by filtration and, if desired, further washed with a solvent. The benzoate ester may be dried by any conventional technique, such as drying in a tray dryer, vacuum dryer, or air oven. Drying may be carried out in a vacuum oven at a temperature of about 30°C to about 60°C.
[0046] The purity of the crystallizable monoterpene (or sesquiterpene) derivative, and therefore the purity of the monoterpene (or sesquiterpene), can be further improved by recrystallization. Various techniques can be used, such as single-solvent recrystallization, multi-solvent recrystallization, hot filtration recrystallization, and other suitable recrystallization techniques known in the art. Wikipedia--Recrystallization; Retrieved from URL: http: / / en.wikipedia.org / wiki / Recrystallization(chemistry).
[0047] For example, U.S. Patent No. Re. 32,241 describes an apparatus having a component that crystallizes on a cooling surface as the component-containing material flows downward. U.S. Patent No. 4,666,456 describes the continuous partial crystallization of a compound from a liquid mixture, in which the mixture is fed through a cascade of cooling sections. U.S. Patent No. 5,127,921 provides a multi-stage recrystallization method that involves controlling reflux ratio conditions by adjusting the amount of crystal and mother liquor reflux material.
[0048] The purity of the perillyl alcohol produced by the above process can be greater than about 98.5% (w / w) [i.e., greater than about 98.5% (w / w)], greater than about 99% (w / w), greater than about 99.5% (w / w), or greater than about 99.9% (w / w).
[0049] In certain embodiments, the compounds of the present invention may contain one or more chiral centers. The term "purity" may also include chiral purity. The stereoisomeric purity of a monoterpene (or sesquiterpene) refers to the chemical purity and / or chiral purity of the stereoisomer. For example, the purity of (S)-perillyl alcohol may include both the chemical purity and chiral purity of (S)-perillyl alcohol. The stereoisomeric chiral purity of a monoterpene (or sesquiterpene) may be greater than about 98.5% (w / w), greater than about 99% (w / w), greater than about 99.5% (w / w), or greater than about 99.9% (w / w).
[0050] The chiral purity of (S)-perillyl alcohol can be greater than about 98.5% (w / w), greater than about 99% (w / w), greater than about 99.5% (w / w), or greater than about 99.9% (w / w). In certain embodiments, the specific rotation of (S)-perillyl alcohol of the present invention can range from −87.95 degrees to −91.9 degrees when measured at 22° C. at a sample concentration of 1 g / ml in MeOH [see Table 1 for examples of specific rotations of (S)-perillyl alcohol]. [Table 1]
[0051] The purity of monoterpenes (or sesquiterpenes) can be analyzed by gas chromatography (GC) or high-pressure liquid chromatography (HPLC). Other techniques for assaying the purity of monoterpenes (or sesquiterpenes) and for determining the presence of impurities include, but are not limited to, nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), GC-MS, infrared spectroscopy (IR), and thin-layer chromatography (TLC). WHO Specifications and Evaluations for Public Health Pesticides: Malathion, World Health Organization, 2003. Chiral purity can be assessed by chiral GC or by measuring optical rotation.
[0052] Alternatively, the monoterpene (or sesquiterpene) can be purified by methods other than crystallization of the derivative. For example, a monoterpene (or sesquiterpene) derivative can be prepared when the derivative has physicochemical properties (e.g., solubility or polarity) that differ from those of its isomers, structural variants, or contaminants (those present in the starting material). Thus, the monoterpene (or sesquiterpene) derivative can be separated from the monoterpene (or sesquiterpene) by a suitable separation technique known in the art, such as preparative chromatography.
[0053] The purified monoterpene (or sesquiterpene) may be stable after storage. For example, after storage at about 5° C. for at least three months, the composition may contain greater than about 98.5% (w / w), greater than about 99% (w / w), greater than about 99.5% (w / w), or greater than about 99.9% (w / w) of the monoterpene (or sesquiterpene). After storage at 25° C. and 60% relative humidity for at least three months, the composition may contain greater than about 98.5% (w / w), greater than about 99% (w / w), greater than about 99.5% (w / w), or greater than about 99.9% (w / w) of the monoterpene (or sesquiterpene).
[0054] The present invention also provides methods for using monoterpenes (or sesquiterpenes) to treat diseases, such as cancer or other nervous system disorders. The monoterpenes (or sesquiterpenes) can be administered alone or in combination with radiation, surgery, or chemotherapy. The monoterpenes or sesquiterpenes can also be co-administered with antiviral, anti-inflammatory, or antibiotic agents. The agents can be administered simultaneously or sequentially. The monoterpenes (or sesquiterpenes) can be administered before, during, or after the administration of other active agents.
[0055] Monoterpenes (or sesquiterpenes) can also be used as solvents or penetration enhancers to deliver therapeutic substances to lesion sites. For example, monoterpenes (or sesquiterpenes) can be used as solvents or penetration enhancers to deliver chemotherapeutic agents to tumor cells. Monoterpenes or sesquiterpenes can also be used as solvents for vaccines, which can be delivered by any suitable route, such as intranasal.
[0056] The present invention also provides the use of monoterpene or sesquiterpene derivatives, such as perillyl alcohol carbamate derivatives. For example, the perillyl alcohol derivative can be perillyl alcohol carbamate. The perillyl alcohol derivative can be perillyl alcohol conjugated (bound) to a therapeutic agent, such as a chemotherapeutic agent. The monoterpene (or sesquiterpene) derivative can be formulated into a pharmaceutical composition, wherein the monoterpene (or sesquiterpene) derivative is present in an amount ranging from about 0.01% (w / w) to about 100% (w / w), 0.1% (w / w) to about 80% (w / w), about 1% (w / w) to about 70% (w / w), about 10% (w / w) to about 60% (w / w), or about 0.1% (w / w) to about 20% (w / w). The composition can be administered alone or co-administered with radiation or another substance (e.g., a chemotherapeutic agent) to treat a disease, such as cancer. Treatment can be sequential, in which the monoterpene (or sesquiterpene) derivative is administered before or after the administration of the other substance. For example, perillyl alcohol carbamate can be used to sensitize cancer patients to radiation or chemotherapy. Alternatively, the substances can be administered simultaneously. The route of administration can vary and can include inhalation, intranasal, oral, transdermal, intravenous, subcutaneous, or intramuscular injection. The present invention also provides a method for treating a disease, such as cancer, comprising delivering a therapeutically effective amount of a monoterpene (or sesquiterpene) derivative to a patient.
[0057] Derivatives of monoterpenes (or sesquiterpenes) include, but are not limited to, carbamates, esters, ethers, alcohols, and aldehydes of monoterpenes (or sesquiterpenes). Monoterpene (or sesquiterpene) alcohols can be derivatized to carbamates, esters, ethers, aldehydes, or acids. Carbamates are functional groups based on the carbonyl groups adjacent to the oxygen and nitrogen. [ka]
[0058] R refers to a class of compounds that share the same 1 , R 2 and R 3 R can be a group such as alkyl, aryl, etc., which may be substituted. The R groups on the nitrogen and oxygen may form a ring. 1 -OH can be a monoterpene (e.g., POH). 2 -NR 3 The moiety can be a therapeutic agent.
[0059] Carbamates can be synthesized by reacting an isocyanate with an alcohol or by reacting a chloroformate with an amine. Carbamates can be synthesized by reactions utilizing phosgene or a phosgene equivalent. For example, carbamates can be synthesized by reacting phosgene gas, diphosgene, or a solid phosgene precursor, such as triphosgene, with two amines, or an amine and an alcohol. Carbamates (also known as urethanes) can also be produced by reacting a urea intermediate with an alcohol. Dimethyl carbonate and diphenyl carbonate are also used to produce carbamates. Alternatively, carbamates can be synthesized by reacting an alcohol and / or amine precursor with an ester-substituted diaryl carbonate, such as bismethylsalicylcarbonate (BMSC). U.S. Patent Publication No. 20100113819. Carbamates can be synthesized by the following approach: [ka]
[0060] Suitable reaction solvents include, but are not limited to, tetrahydrofuran, dichloromethane, dichloroethane, acetone, and diisopropyl ether. The reaction can be carried out at temperatures ranging from about -70°C to about 80°C, or from about -65°C to about 50°C. The molar ratio of perillyl chloroformate to substrate R-NH2 can range from about 1:1 to about 2:1, from about 1:1 to about 1.5:1, from about 2:1 to about 1:1, or from about 1.05:1 to about 1.1:1. Suitable bases include, but are not limited to, organic bases such as triethylamine, potassium carbonate, N,N'-diisopropylethylamine, butyllithium, and potassium t-butoxide. Alternatively, carbamates can be synthesized by the following approach. [ka]
[0061] Suitable reaction solvents include, but are not limited to, dichloromethane, dichloroethane, toluene, diisopropyl ether, and tetrahydrofuran. The reaction can be carried out at a temperature ranging from about 25° C. to about 110° C., or from about 30° C. to about 80° C., or at a temperature of about 50° C. The molar ratio of perillyl alcohol to substrate R—N═C═O can range from about 1:1 to about 2:1, from about 1:1 to about 1.5:1, from about 2:1 to about 1:1, or from about 1.05:1 to about 1.1:1.
[0062] The esters of monoterpene (or sesquiterpene) alcohols of the present invention can be derived from inorganic or organic acids. Inorganic acids include, but are not limited to, phosphoric acid, sulfuric acid, and nitric acid. Organic acids include, but are not limited to, carboxylic acids such as benzoic acid, fatty acids, acetic acid, and propionic acid, as well as any therapeutic agent containing at least one carboxylic acid functional group. Examples of esters of monoterpene (or sesquiterpene) alcohols include, but are not limited to, carboxylic acid esters (e.g., benzoic acid esters, fatty acid esters (e.g., palmitic acid esters, linoleic acid esters, stearic acid esters, butyryl esters, and oleic acid esters), acetates, propionates (or propanoates), and formates), phosphates, sulfates, and carbamates (e.g., N,N-dimethylaminocarbonyl). Wikipedia - Ester; Retrieved from URL: http: / / en.wikipedia.org / wiki / Ester
[0063] Specific examples of monoterpenes that can be used in the present invention include perillyl alcohol (commonly abbreviated as POH). Derivatives of perillyl alcohol include perillyl alcohol carbamate, perillyl alcohol ester, perillyl aldehyde, dihydroperillic acid, perillic acid, perillyl aldehyde derivatives, dihydroperillic acid ester, and perillic acid. Derivatives of perillyl alcohol can also include its oxidation derivatives and nucleophilic / electrophilic addition derivatives. U.S. Patent Publication No. 20090031455, U.S. Patent Nos. 6,133,324, and 3,957,856. Numerous examples of perillyl alcohol derivatives have been reported in the chemical literature (see Appendix A: CAS Scifinder search output file (accessed January 25, 2010)).
[0064] In certain embodiments, POH carbamate is synthesized by a process comprising reacting a first reactant, perillyl chloroformate, with a second reactant, such as dimethyl cerocoxib (DMC), temozolomide (TMZ), and rolipram. The reaction can be carried out in the presence of tetrahydrofuran and a base, such as n-butyllithium. Perillyl chloroformate can be prepared by reacting POH with phosgene. For example, POH conjugated to temozolomide via a carbamate bond can be synthesized by reacting temozolomide with oxalyl chloride and then reacting with perillyl alcohol. The reaction can be carried out in the presence of 1,2-dichloroethane.
[0065] POH carbamates encompassed by the present invention include, but are not limited to, 4-(bis-N,N'-4-isopropenylcyclohex-1-enylmethyloxycarbonyl[5-(2,5-dimethylphenyl)-3-trifluoromethylpyrazol-1-yl]benzenesulfonamide, 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxo-pyrrolidine-1-carboxylic acid 4-isopropenylcyclohex-1-enylmethyl ester, and (3-methyl 4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl)carbamic acid-4-isopropenylcyclohex-1-enylmethyl ester. Details of the chemical reactions leading to these compounds are provided in the Examples below.
[0066] Monoterpenes (or sesquiterpenes) or perillyl alcohol carbamates thereof can be used to treat nervous system cancers, such as malignant gliomas (e.g., astrocytoma, anaplastic astrocytoma, glioblastoma multiforme), retinoblastoma, pilocytic astrocytoma (grade I), meningioma, metastatic brain tumors, neuroblastoma, pituitary adenoma, skull base meningioma, and skull base cancer. As used herein, the term "nervous system tumor" refers to a condition in which a subject has malignant proliferation of nervous system cells.
[0067] Cancers that may be treated with the monoterpene (or sesquiterpene) or perillyl alcohol carbamate compositions include, but are not limited to, lung cancer, ear, nose and throat cancer, leukemia, colon cancer, melanoma, pancreatic cancer, breast cancer, prostate cancer, mammary cancer, hematopoietic cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, breast cancer, cervical cancer, choriocarcinoma, colon and rectal cancer, connective tissue cancer, digestive system cancer, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer, and intraepithelial neoplasia. tumors, kidney cancer, laryngeal cancer, leukemias such as acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, liver cancer, lymphomas such as Hodgkin's lymphoma and non-Hodgkin's lymphoma, myeloma, fibroma, neuroblastoma, oral cancer (e.g., lip, tongue, mouth, and pharynx), ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, kidney cancer, respiratory system cancer, sarcoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, urinary system cancer, and other carcinomas and sarcomas.
[0068] The present invention also provides a method for treating CNS disorders, including, but not limited to, primary degenerative neurological disorders, such as Alzheimer's disease, Parkinson's disease, psychiatric disorders, psychosis, and depression. The treatment can involve using purified monoterpenes or sesquiterpenes alone or in combination with current medications used to treat Parkinson's disease, Alzheimer's disease, or psychiatric disorders. For example, purified monoterpenes or sesquiterpenes can be used as a solvent for inhalation of current medications used to treat Parkinson's disease, Alzheimer's disease, or psychiatric disorders.
[0069] Monoterpenes, sesquiterpenes, or perillyl alcohol carbamates can be used in combination with radiation therapy. In one embodiment, the present invention provides a method for treating tumor cells, such as malignant glioma cells, with radiation, in which the cells are treated with an effective amount of a monoterpene, such as perillyl alcohol, and then exposed to radiation. Monoterpene treatment can be administered before, during, and / or after radiation. For example, monoterpenes or sesquiterpenes can be administered continuously starting one week before the start of radiation therapy and continuing for two weeks after the completion of radiation therapy. U.S. Patent Nos. 5,587,402 and 5,602,184.
[0070] The monoterpene, sesquiterpene, or perillyl alcohol carbamate may be used in combination with at least one therapeutic agent, including, but not limited to, chemotherapeutic agents, immunotherapeutic agents, and antibodies (e.g., monoclonal antibodies). Anticancer agents that may be used in combination with the purified monoterpene or sesquiterpene may have one or more of the following effects on cancer cells or subjects: cell death, reduced cell proliferation, reduced cell number, suppression of cell growth, apoptosis, necrosis, mitotic cell death, cell cycle arrest, reduced cell size, reduced cell division, reduced cell survival, reduced cell metabolism, markers of cell damage or cytotoxicity, indirect indicators of cell damage or cytotoxicity, such as tumor shrinkage, improved subject survival, or disappearance of markers associated with undesired, unwanted, or abnormal cell proliferation. U.S. Patent Publication No. 20080275057.
[0071] The present invention also includes mixtures and / or co-formulations comprising a monoterpene (or sesquiterpene) or perillyl alcohol carbamate and at least one therapeutic agent, such as, but not limited to, a chemotherapeutic agent.
[0072] Chemotherapeutic agents include, but are not limited to, DNA alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducers, platinum compounds, antimetabolites, vincalkaloids, taxanes, epothilones, enzyme inhibitors, receptor antagonists, therapeutic antibodies, tyrosine kinase inhibitors, boron radiosensitizers (i.e., Velcade), and chemotherapy combination therapies.
[0073] In one embodiment, the present invention provides a method of treating tumor cells, e.g., malignant glioma cells, with chemotherapy, wherein the cells are treated with an effective amount of a monoterpene, e.g., perillyl alcohol, and then subjected to chemotherapy. The monoterpene treatment can be administered before, during, and / or after chemotherapy.
[0074] DNA alkylating agents are well known in the art and are used to treat various tumors.Non-limiting examples of DNA alkylating agents include nitrogen mustards, such as mechlorethamine, cyclophosphamide (ifosfamide, trofosfamide), chlorambucil (melphalan, prednimustine), bendamustine, uramustine and estramustine; nitrosoureas, such as carmustine (BCNU), lomustine (semustine), fotemustine, nimustine, ranimustine and streptozocin; alkylsulfonates, such as busulfan (mannosulfan, treosulfan); aziridines, such as carboquone, thioTEPA, triaziquone, triethylenemelamine; hydrazine (procarbazine); triazenes, such as dacarbazine and temozolomide; altretamine and mitobronitol.
[0075] Non-limiting examples of topoisomerase I inhibitors include camptothecin derivatives such as CPT-11 (irinotecan), SN-38, APC, NPC, campothecin, topotecan, exatecan mesylate, 9-nitrocamptothecin, 9-aminocamptothecin, lurtotecan, rubitecan, ciratecan, gimatecan, diflomotecan, extatecan, BN-80927, DX-8951f, and MAG-CPT [described in Pommier Y. (2006) Nat. Rev. Cancer 6(10):789-802 and U.S. Patent Publication No. 200510250854]; protoberberine alkaloids and their derivatives such as berberrubine and coralyne [Li et al., (2000) Biochemistry 39(24):7107-7116 and Gatto et al. (1996) Cancer Res. 15(12):2795-2800]; phenanthroline derivatives such as benzo[i]phenanthridine, nitidine, and fagaronine [described in Makhey et al. (2003) Bioorg. Med. Chem. 11(8):1809-1820]; terbenzimidazole and its derivatives [described in Xu (1998) Biochemistry 37(10):3558-3566]; and anthracycline derivatives such as doxorubicin, daunorubicin, and mitoxantrone [described in Foglesong et al. (1992) Cancer Res. Chemother. Pharmacol. 30(2):123-25; Crow et al. (1994) J. Med. Chem. 37(19):31913194; and Crespi et al. (1986) Biochem. Biophys. Res. Commun. 136(2):521-8. Topoisomerase II inhibitors include, but are not limited to, etoposide and teniposide.Dual topoisomerase I and II inhibitors include, but are not limited to, saintopin and other naphthecenediones, DACA and other acridine-4-carboxamines, intoplicin and other benzopyridoindoles, TAS-I03 and other 7H-indeno[2,1-c]quinolin-7-ones, pyrazoloacridines, XR11576 and other benzophenazines, XR5944 and other dimeric compounds, 7-oxo-7H-dibenzo[f,ij]isoquinolines and 7-oxo-7H-benzo[e]perimidine, and anthracenyl-amino acid conjugates [described in Denny and Baguley (2003) Curr. Top. Med. Chem. 3(3):339-353]. Several substances inhibit topoisomerase II and have DNA intercalation activity, including, but not limited to, the anthracyclines (aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin) and the anthracenediones (mitoxantrone and pixantrone).
[0076] Examples of endoplasmic reticulum stress inducers include, but are not limited to, dimethyl-celecoxib (DMC), nelfinavir, celecoxib, and boron radiosensitizers [i.e., Velcade (bortezomib)].
[0077] Platinum-based compounds are a subclass of DNA alkylating agents. Non-limiting examples of such agents include carboplatin, cisplatin, nedaplatin, oxaliplatin, triplatin tetranitrate, satraplatin, aroplatin, lobaplatin, and JM-216 (see McKeage et al., (1997) J. Clin. Oncol. 201:1232-1237 and generally CHEMOTHERAPY FOR GYNECOLOGICAL NEOPLASM, CURRENT THERAPY AND NOVEL APPROACHES, in the Series Basic and Clinical Oncology, Angioli et al., eds., 2004).
[0078] "FOLFOX" is an abbreviation for a type of combination therapy used to treat colorectal cancer. It includes 5-FU, oxaliplatin, and leucovorin. Information about this treatment is available on the National Cancer Institute's website, cancer.gov (last accessed January 16, 2008).
[0079] "FOLFOX / BV" is an abbreviation for a type of combination therapy used to treat colorectal cancer. This therapy includes 5-FU, oxaliplatin, leucovorin, and bevacizumab. Furthermore, "XELOX / BV" is another combination therapy used to treat colorectal cancer, which includes a prodrug of 5-FU known as capecitabine (Xeloda) in combination with oxaliplatin and bevacizumab. Information about these therapies is available on the National Cancer Institute's website, cancer.gov, and the National Comprehensive Cancer Network's website, nccn.org (last accessed May 27, 2008).
[0080] Non-limiting examples of antimetabolites include: folate-based, i.e., dihydrofolate reductase inhibitors, such as aminopterin, methotrexate, and pemetrexed; thymidylate synthase inhibitors, such as raltitrexed, pemetrexed; purine-based, i.e., adenosine deaminase inhibitors, such as pentostatin, thiopurines, e.g., thioguanine and mercaptopurine, halogenated / ribonucleotide reductase inhibitors, inhibitors, such as cladribine, clofarabine, fludarabine, or guanine / guanosine:thiopurines, such as thioguanine; or pyrimidine-based, i.e., cytosine / cytidine:hypomethylating agents, such as azacytidine and decitabine, DNA polymerase inhibitors, such as cytarabine, ribonucleotide reductase inhibitors, such as gemcitabine, thymine / thymidine:thymidylate synthase inhibitors, such as fluorouracil (5-FU). Equivalents of 5-FU include its prodrugs, analogs and derivatives, such as 5'-deoxy-5-fluorouridine (doxifluroidin), 1-tetrahydrofuranyl-5-fluorouracil (futorafur), capecitabine (Xeloda), SI (MBMS-247616, consisting of tegafur and two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate), ralitrexed (Tomudex), nolatrexed (Thymitaq, AG337), LY231514 and ZD9331 (described, for example, in Papamicheal (1999) The Oncologist 4:478-487).
[0081] Examples of vincalkaloids include, but are not limited to, vinblastine, vincristine, vinflunine, vindesine, and vinorelbine.
[0082] Examples of taxanes include, but are not limited to, docetaxel, larotaxel, ortataxel, paclitaxel, and tesetaxel.An example of an epothilone is iabepilone.
[0083] Examples of enzyme inhibitors include, but are not limited to, farnesyltransferase inhibitors (tipifamib); CDK inhibitors (alvocidib, seliciclib); proteasome inhibitors (bortezomib); phosphodiesterase inhibitors (anagrelide, rolipram); IMP dehydrogenase inhibitors (tiazofurin); and lipoxygenase inhibitors (masoprocol). Examples of receptor antagonists include, but are not limited to, ERAs (atrasentan), retinoid X receptor (bexarotene), and sex steroids (testolactone).
[0084] Examples of therapeutic antibodies include, but are not limited to, anti-HER1 / EGFR (cetuximab, panitumumab), anti-HER2 / neu (erbB2) receptor (trastuzumab), anti-EpCAM (catumaxomab, edrecolomab), anti-VEGF-A (bevacizumab), anti-CD20 (rituximab, tositumomab, ibritumomab), anti-CD52 (alemtuzumab), and anti-CD33 (gemtuzumab); see U.S. Pat. Nos. 5,776,427 and 7,601,355.
[0085] Examples of tyrosine kinase inhibitors include, but are not limited to, inhibitors against ErbB: HER1 / EGFR (erlotinib, gefitinib, lapatinib, vandetanib, sunitinib, neratinib); HER2 / neu (lapatinib, neratinib); RTK class III: C-kit (axitinib, sunitinib, sorafenib), FLT3 (lestaurtinib), PDGFR (axitinib, sunitinib, sorafenib); and VEGFR (vandetanib, semaxanib, cediranib, axitinib, sorafenib); bcr-abl (imatinib, nilotinib, dasatinib); Src (bosutinib) and Janus kinase 2 (lestaurtinib).
[0086] Cetuximab is an example of an anti-EGFR antibody. It is a chimeric human / mouse monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Biologically equivalent antibodies are defined herein as modified antibodies and antibodies that bind to the same epitope on the EGFR antigen and produce a substantially equivalent (equivalent) biological response (e.g., inhibition of EGFR ligand binding, inhibition of EGFR receptor activation, and disruption of cell proliferation by blocking downstream signaling of the EGFR pathway).
[0087] "Lapatinib" (Tykerb®) is a dual inhibitor of EGFR and erbB-2. Lapatinib is being studied in numerous clinical trials as an anticancer monotherapy and in combination with trastuzumab, capecitabine, letrozole, paclitaxel, and FOLF1R1 (irinotecan, 5-fluorouracil, and leucovorin). It is currently in Phase III trials for the oral treatment of metastatic breast, head and neck, lung, gastric, kidney, and bladder cancers.
[0088] Chemical equivalents of lapatinib are small molecules or compounds that are tyrosine kinase inhibitors (TKIs) or that are HER-1 or HER-2 inhibitors. Several TKIs have been shown to have effective antitumor activity and are already approved or in clinical trials. Examples of such agents include, but are not limited to, Zactima (ZD6474), Iressa (gefitinib), and Tarceva (erlotinib), imatinib mesylate (STI571; Gleevec), erlotinib (OSI-1774; Tarceva), canertinib (CI1033), semaxinib (SU5416), vatalanib (PTK787 / ZK222584), sorafenib (BAY 43-9006), Sutent (SUI 1248), and leflutomide (SU101). Bioisosteres of lapatinib are peptides, antibodies, or antibody derivatives thereof that are HER-1 and / or HER-2 inhibitors. Examples of such agents include, but are not limited to, the humanized antibodies trastuzumab and Herceptin.
[0089] PTK / ZK is a broadly specific, "small" molecule tyrosine kinase inhibitor that targets all VEGF receptors (VEGFRs), platelet-derived growth factor (PDGF) receptors, c-KIT, and c-Fms (Drevs (2003) Idrugs 6(8):787-794). PTK / ZK is a targeted drug that blocks angiogenesis and lymphangiogenesis by suppressing the activity of all known receptors that bind to VEGF, including VEGFR-1 (Flt-1), VEGFR-2 (KDR / Flk-1), and VEGFR-3 (Flt-4). The chemical name of PTK / ZK is 1-[4-chloroanilino]-4-[4-pyridylmethyl]phthalazine succinate or 1-phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-butanedioate (1:1). Synonyms and analogs of PTK / TK are known as vatalanib, CGP79787D, PTK787 / ZK222584, CGP-79787, DE-00268, PTK-787, PTK787A, VEGFR-TK inhibitors, ZK222584 and ZK.
[0090] Chemotherapeutic agents that may be used in combination with the purified monoterpene, sesquiterpene, or perillyl alcohol carbamate may also include amsacrine, trabectedin, retinoids (alitretinoin, tretinoin), arsenic trioxide, asparagine-depleting agents (asparaginase / pegaspargase), celecoxib, demecolcine, eleclomol, elsamitrucin, etoglucide, lonidamine, lucantone, mitoguazone, mitotane, oblimersen, temsirolimus, and vorinostat.
[0091] The compositions and methods of the present invention can be used to reduce levels of Ras proteins. The Ras family is a protein family of small GTPases involved in cell signaling. Activation of Ras signaling leads to cell growth, differentiation, and survival. Mutations in the ras gene permanently activate it, causing inappropriate intracellular communication, even in the absence of extracellular signals. Because these signals lead to cell growth and division, dysregulation of Ras signaling can ultimately lead to oncogenesis and cancer. Activating mutations in Ras are found in 20-25% of all human tumors and up to 90% of specific tumor types. Goodsell DS (1999). Downward J., "The molecular perspective: the ras oncogene." Oncologist 4(3):263-4. (January 2003). "Targeting RAS signaling pathways in cancer therapy." Nat. Rev. Cancer 3(1):11-22. Members of the Ras family include, but are not limited to, HRAS; KRAS; NRAS; DIRAS1; DIRAS2; DIRAS3; ERAS; GEM; MRAS; NKIRAS1; NKIRAS2; NRAS; RALA; RALB; RAP1A; RAP1B; RAP2A; RAP2B; RAP2C; RASD1; RASD2; RASL10A; RASL10B; RASL11A; RASL11B; RASL12; REM1; REM2; RERG; RERGL; RRAD; RRAS; and RRAS. Wennerberg K, Rossman KL, Der CJ (March 2005). "The Ras superfamily at a glance". J. Cell. Sci. 118(Pt 5):843-6.
[0092] The compositions and methods of the invention can be used to increase paracellular permeability, for example, the paracellular permeability of endothelial or epithelial cells. The compositions and methods of the invention can be used to increase the permeability of the blood-brain barrier.
[0093] The compositions and methods of the present invention can be used to reduce or inhibit angiogenesis. The compositions and methods of the present invention can reduce or inhibit the production of pro-angiogenic cytokines, including, but not limited to, vascular endothelial growth factor (VEGF) and interleukin 8 (IL8).
[0094] The purified monoterpene, sesquiterpene, or perillyl alcohol carbamate may be used in combination with an angiogenesis inhibitor, including, but not limited to, angiostatin, angiozyme, antithrombin III, AG3340, VEGF inhibitors (e.g., anti-VEGF antibodies), batimastat, bevacizumab (Avastin), BMS-275291, CAI, 2C3, and HuMV833. Canstatin, captopril, carboxyamidotriazole, cartilage-derived inhibitor (CDI), CC-5013, 6-O-(chloroacetyl-carbonyl)-fumagillol, COL-3, combretastatin, combretastatin A4 phosphate, dalteparin, EMD121974 (cilengitide), endostatin, erlotinib, gefitinib (Iressa), genistein, halofuginone hydrobromide, Id1, Id3, IM862, imatinib mesylate, IMC-IC11-inducible protein 10, interferon-alpha, interleukin-12, lavendustin A, LY317615 or AE-941, marimastat methicone, mspin, medroxpregesterone acetate, Meth-1, Meth-2, 2-methoxyestradiol (2-ME), neovastat, oteopontin cleavage product, PEX, pigment epithelial growth factor (PEGF), platelet factor 4, prolactin fragment, proliferin-related protein (PRP), PTK787 / ZK222584, ZD6474, recombinant human platelet factor 4 (rPF4), restin, squalamine, SU5416, SU6668, SU11248, suramin, taxol, tecogalan, thalidomide, thrombospondin, TNP-470, troponin-1, vasostatin, VEG1, VEGF-trap, and ZD6474.
[0095] Non-limiting examples of angiogenesis inhibitors also include tyrosine kinase inhibitors, such as inhibitors of the tyrosine kinase receptors Flt-1 (VEGFR1) and Flk-1 / KDR (VEGFR2), inhibitors of epidermal-derived, fibroblast-derived, or platelet-derived growth factors, MMP (matrix metalloproteinase) inhibitors, integrin blockers, pentosan polysulfate, angiotensin II antagonists, cyclooxygenase inhibitors (e.g., nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, and selective cyclooxygenase 2 inhibitors, such as celecoxib and rofecoxib), and steroidal anti-inflammatory drugs (e.g., corticosteroids, mineralocorticoids, dexamethasone, prednisone, prednisolone, methylpred, betamethasone).
[0096] Other therapeutic substances that regulate or inhibit angiogenesis and can be used in combination with the compounds of the present invention include substances that regulate or inhibit the coagulation and fibrinolysis systems. Examples of such substances that regulate or inhibit the coagulation and fibrinolysis pathways include, but are not limited to, heparin, low molecular weight heparin, and carboxypeptidase U inhibitor (also known as an inhibitor of active thrombin-activatable fibrinolysis inhibitor [TAFIa]). U.S. Patent Publication No. 20090328239, U.S. Patent No. 7,638,549.
[0097] The present invention also provides a method for improving an immunomodulatory therapeutic response, comprising exposing cells to an effective amount of a monoterpene or cis-quiterpene, such as perillyl alcohol, before or during immunomodulatory therapy. Preferred immunomodulators include cytokines, such as interleukins, lymphokines, monokines, interferons, and chemokines.
[0098] The present invention further provides compositions in which a purified monoterpene (or sesquiterpene) functions as a solvent or penetration enhancer. In one embodiment, the monoterpene is perillyl alcohol. Examples of therapeutic agents are described below. The compositions may further comprise one or more pharmaceutically acceptable carriers, cosolvents, or other penetration enhancers.
[0099] In one embodiment, the composition contains the following components: a therapeutic agent; at least about 0.03% (v / v) of a monoterpene (or sesquiterpene), such as perillyl alcohol; at least about 2.6% (v / v) of a cosolvent, which may be 1.3% (v / v) of a polyol, such as glycerol or its equivalent; and at least about 1.3% (v / v) of ethanol or its equivalent.
[0100] Other penetration enhancers that may be used with purified monoterpenes (or sesquiterpenes) include, but are not limited to, fatty acid esters of glycerin, such as capric acid, caprylic acid, dodecylic acid, and oleic acid; fatty acid esters of isosorbide, sucrose, and polyethylene glycol; caproyl lactylate; laureth-2; laureth-2 acetate; laureth-2 benzoate; laureth-3 carboxylic acid; laureth-4; laureth-5 carboxylic acid; oleth-2; and glyceryl Pyroglutamate oleate; glyceryl oleate; N-lauroyl sarcosine; N-myristoyl sarcosine; noctyl-2-pyrrolidone; lauraminopropionic acid; polypropylene glycol-4-laureth-2; polypropylene glycol-4-laureth-5 dimethyl lauramide; lauramide diethanolamine (DEA), lauryl pyroglutamate (LP), glyceryl monolaurate (GML), glyceryl monocaprylate, glyceryl monocaprate, glyceryl monooleate (GMO), and sorbitan monolaurate. Polyols or ethanol can function as penetration enhancers or cosolvents. For additional penetration enhancers, see U.S. Patent Nos. 5,785,991, 5,843,468, 5,882,676, and 6,004,578.
[0101] Co-solvents are well known in the art and include, but are not limited to, glycerol, polyethylene glycol (PEG), glycol, ethanol, methanol, propanol, isopropanol, butanol, and the like.
[0102] The compositions may be administered by any method known in the art, including, but not limited to, intranasal, oral, ophthalmic, intraperitoneal, inhalation, intravenous, ICV, intracisternal injection or infusion, subcutaneous, implant, vaginal, sublingual, urethral (e.g., urethral suppository), subcutaneous, intramuscular, intravenous, transdermal, rectal, sublingual, mucosal, ophthalmic, spinal, intrathecal, intraarticular, intraarterial, intrathecal, bronchial, and lymphatic administration. Topical formulations may be in the form of gels, ointments, creams, aerosols, etc. Intranasal formulations may be delivered as sprays or drops. Transdermal formulations may be administered by transdermal patches or iontophoresis. Inhalation formulations may be delivered using a nebulizer or similar device. The compositions may also take the form of tablets, pills, capsules, semisolids, powders, sustained-release formulations, solutions, suspensions, elixirs, aerosols, or any other suitable composition.
[0103] To prepare such pharmaceutical compositions, one or more purified monoterpenes (or sesquiterpenes) or perillyl alcohol carbamates can be mixed with pharmaceutically acceptable carriers, adjuvants, and / or excipients according to conventional pharmaceutical compounding techniques. Pharmaceutically acceptable carriers that can be used in the compositions include any standard pharmaceutical carrier, such as phosphate-buffered saline, water, and emulsions, such as oil / water or water / oil emulsions, as well as various types of humectants. The compositions may also contain solid pharmaceutical excipients, such as starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, and the like. Liquid and semisolid excipients can be selected from glycerol, propylene glycol, water, ethanol, and various oils, such as those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols. For examples of carriers, stabilizers, and adjuvants, see Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990). The composition may also contain stabilizers and preservatives.
[0104] As used herein, the term "therapeutically effective amount" refers to an amount sufficient to treat a specified disorder or disease or to produce a pharmacological response that treats the disorder or disease. Methods for determining the most effective means and dosage may vary depending on the composition used for treatment, the purpose of treatment, the target cell being treated, and the subject being treated. Therapeutic dosages may generally be determined to optimize safety and efficacy. Single or multiple administrations may be carried out, with the dosage level and pattern selected by the treating physician. Appropriate dosage formulations and methods of administration of therapeutic agents can be readily determined by those skilled in the art. For example, compositions may be administered at about 0.01 mg / kg to about 200 mg / kg, about 0.1 mg / kg to about 100 mg / kg, or about 0.5 mg / kg to about 50 mg / kg. When the compounds described herein are co-administered with another agent or therapy, the effective amount may be less than when the therapeutic agent is used alone.
[0105] The present invention also provides the composition for intranasal administration. Accordingly, the composition may further comprise a penetration enhancer. Southall et al., Developments in Nasal Drug Delivery, 2000. The purified monoterpene (or sesquiterpene) or perillyl alcohol carbamate derivative can be administered intranasally in a liquid form, such as a solution, emulsion, suspension, or drop, or in a solid form, such as a powder, gel, or ointment. Devices for delivering intranasal medications are well known in the art. Nasal drug delivery can be achieved using devices including, but not limited to, intranasal inhalers, intranasal spray devices, atomizers, nasal spray bottles, unit-dose containers, pumps, droppers, squeeze bottles, nebulizers, metered-dose inhalers (MDIs), pressurized-dose inhalers, insufflators, and bidirectional devices. Nasal delivery devices can be metered to administer an accurate, effective dose to the nasal cavity. Nasal delivery devices can be single-unit or multi-unit delivery devices. In a specific example, the ViaNase Electronic Atomizer from Kurve Technology (Bethell, Wash.) (http: / / www.kurvetech.com) can be used in the present invention. The compounds of the present invention can be delivered via a tube, catheter, syringe, pack tail, cotton ball, nasal tampon, or by submucosal injection. U.S. Patent Publication Nos. 20090326275, 20090291894, 20090281522, and 20090317377.
[0106] Purified monoterpenes (or sesquiterpenes) or perillyl alcohol carbamate derivatives can be formulated as aerosols using standard methods. The monoterpenes (or sesquiterpenes) can be formulated with or without a solvent, and with or without a carrier. The formulation can be a solution or an aqueous emulsion containing one or more surfactants. For example, aerosol sprays can be produced from pressurized containers using suitable propellants, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, hydrocarbons, compressed air, nitrogen, carbon dioxide, or other suitable gases. Dosage units can be determined by providing a valve to deliver a metered amount. Pump spray dispensers can dispense metered doses or doses with a specific particle or droplet size. As used herein, the term "aerosol" refers to a suspension of solution droplets or fine solid particles in a gas. Specifically, aerosols include gas-containing suspensions of monoterpene (or sesquiterpene) droplets, which can be generated in any suitable device, such as an MDI, a nebulizer, or a mist sprayer. Aerosols also include dry powder compositions of the compositions of the present invention suspended in air or other carrier gases. Gonda (1990) Critical Reviews in Therapeutic Drug Carrier Systems 6:273-313; Raeburn et al. (1992) Pharmacol. Toxicol. Methods 27:143-159.
[0107] Purified monoterpenes (or sesquiterpenes) or perillyl alcohol carbamates can be delivered to the nasal cavity as powders in the form of microspheres delivered by nasal inhalers. The monoterpenes (or sesquiterpenes) can be absorbed onto a solid surface, such as a carrier. The powders or microspheres can be administered in a dry, air-dispensable form. The powders or microspheres can be stored in the container of the inhaler. Alternatively, the powders or microspheres can be filled into capsules, such as gelatin capsules, or other single-dose units suitable for nasal administration.
[0108] Pharmaceutical compositions can be delivered to the nasal cavity by directly placing the composition in the nasal cavity, for example, in the form of a gel, ointment, nasal emulsion, lotion, cream, nasal tampon, dropper, or bioadhesive strip. In certain embodiments, it may be desirable to extend the residence time of the pharmaceutical composition in the nasal cavity, for example, to enhance absorption. Thus, the pharmaceutical composition can be formulated, if desired, using bioadhesive polymers, gums (e.g., xanthan gum), chitosan (e.g., highly purified cationic polysaccharides), pectin (or any carbohydrate that thickens or emulsifies like a gel when applied to the nasal mucosa), microspheres (e.g., starch, albumin, dextran, cyclodextrin), gelatin, liposomes, carbamer, polyvinyl alcohol, alginate, acacia, chitosan, and / or cellulose (e.g., methyl or propyl; hydroxyl or carboxy; carboxymethyl or hydroxypropyl).
[0109] Compositions containing purified monoterpene (or sesquiterpene) or perillyl alcohol carbamate can be administered into the respiratory tract, ie, into the lungs, by oral inhalation.
[0110] Typical delivery systems for inhalable substances include nebulizer inhalers, dry powder inhalers (DPIs) and metered dose inhalers (MDIs).
[0111] Nebulizer devices generate a stream of high velocity air that causes the therapeutic substance in liquid form to spray as a mist. The therapeutic substance is formulated in liquid form as a solution or suspension of appropriately sized particles. In one embodiment, the particles are micronized. The term "micronized" is defined as having about 90% or more of the particles having a diameter of less than about 10 μm. Suitable nebulizer devices are commercially available, for example, from PARI GmbH (Starnberg, Germany). Other nebulizer devices include Respimat (Boehringer Ingelheim) and those disclosed, for example, in U.S. Patent Nos. 7,568,480 and 6,123,068, and WO 97 / 12687. Monoterpenes (or sesquiterpenes) can be formulated for use in nebulizer devices as aqueous solutions or liquid suspensions.
[0112] DPI devices typically administer therapeutic substances in the form of a free-flowing powder that can be dispersed in a patient's airstream during inspiration. DPI devices that use an external energy source can also be used in the present invention. To obtain a free-flowing powder, the therapeutic substance can be formulated with a suitable excipient (e.g., lactose). A dry powder formulation can be produced, for example, by dry-blending dry lactose having a particle size of about 1 μm to 100 μm with micronized particles of a monoterpene (or sesquiterpene). Alternatively, the monoterpene can be formulated in the absence of excipients. The formulation is loaded into a dry powder dispenser or into an inhalation cartridge or capsule for a dry powder delivery device. Examples of commercially available DPI devices include Diskhaler (GlaxoSmithKline, Research Triangle Park, NC) (see, e.g., U.S. Pat. No. 5,035,237); Diskus (GlaxoSmithKline) (see, e.g., U.S. Pat. No. 6,378,519); Turbuhaler (AstraZeneca, Wilmington, Del.) (see, e.g., U.S. Pat. No. 4,524,769); and Rotahaler (GlaxoSmithKline) (see, e.g., U.S. Pat. No. 4,353,365). Other examples of suitable DPI devices are described in U.S. Pat. Nos. 5,415,162, 5,239,993, and 5,715,810 and references therein.
[0113] MDI devices typically use compressed propellant gas to deliver a metered amount of therapeutic substance. Formulations for MDI administration include a solution or suspension of the active ingredient in a liquefied propellant. Examples of propellants include hydrofluoroalkanes (HFAs), such as 1,1,1,2-tetrafluoroethane (HFA134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane (HFA227), and chlorofluorocarbons, such as CCl3F. Additional components of HFA formulations for MDI administration include cosolvents, such as ethanol, pentane, and water; and surfactants, such as sorbitan trioleate, oleic acid, lecithin, and glycerin (see, e.g., U.S. Pat. No. 5,225,183, EP 0717987, and WO 92 / 22286). The formulation is packaged in an aerosol canister, which forms part of the MDI device. Examples of MDI devices specifically developed for use in the presence of HFA propellants are described in U.S. Patent Nos. 6,006,745 and 6,143,227. For examples of suitable formulation manufacturing methods and devices suitable for inhalation administration, see U.S. Patent Nos. 6,268,533, 5,983,956, 5,874,063, and 6,221,398, as well as WO 99 / 53901, WO 00 / 61108, WO 99 / 55319, and WO 00 / 30614.
[0114] Monoterpenes (or sesquiterpenes) or perillyl alcohol carbamates can be encapsulated in liposomes or microcapsules for delivery by inhalation. Liposomes are vesicles composed of a lipid bilayer and an aqueous interior. The lipid membrane can be composed of phospholipids, examples of which include phosphatidylcholines, such as lecithin and lysolecithin; acidic phospholipids, such as phosphatidylserine and phosphatidylglycerol; and sphingophospholipids, such as phosphatidylethanolamine and sphingomyelin. Alternatively, cholesterol can be added. Microcapsules are particles coated with a coating material. For example, the coating material can consist of a mixture of a film-forming polymer, a hydrophobic plasticizer, a surfactant, and / or a lubricant nitrogen-containing polymer. U.S. Patent Nos. 6,313,176 and 7,563,768.
[0115] Because monoterpenes can easily penetrate the dermis, they can be used by topical application alone or in combination with other chemotherapeutic agents for the treatment of localized cancers, such as breast cancer or melanoma. As transdermal delivery agents, monoterpenes can be used in combination with narcotics or analgesics for the transdermal delivery of analgesics.
[0116] The present invention also provides the composition for ocular administration. Accordingly, the composition may further comprise a penetration enhancer. For ocular administration, the compositions described herein may be formulated as a solution, emulsion, suspension, etc. Various vehicles suitable for administering compounds to the eye are known in the art. Specific non-limiting examples are described in U.S. Patent Nos. 6,261,547, 6,197,934, 6,056,950, 5,800,807, 5,776,445, 5,698,219, 5,521,222, 5,403,841, 5,077,033, 4,882,150, and 4,738,851.
[0117] The monoterpene (or sesquiterpene) or perillyl alcohol carbamate can be administered alone or in combination with other drugs for short-term or long-term treatment of the above diseases. The compositions of the present invention can be administered to mammals, preferably humans. Mammals include, but are not limited to, mice, rats, rabbits, monkeys, cows, sheep, pigs, dogs, cats, farm animals, sport animals, pets, horses, and primates.
[0118] The present invention further provides articles of manufacture (e.g., kits) containing purified monoterpenes (or sesquiterpenes) formulated for intranasal administration, and devices for intranasal administration of purified monoterpenes (or sesquiterpenes). The devices for intranasal administration can be intranasal spray devices, atomizers, nebulizers, metered dose inhalers (MDIs), pressurized dose inhalers, injectors, intranasal inhalers, nasal spray bottles, unit dose containers, pumps, droppers, squeeze bottles, or two-way devices. The articles of manufacture can include printed material indicating that the purified monoterpenes (or sesquiterpenes) are used to treat diseases such as cancer or other nervous system disorders. The printed material can indicate that the monoterpenes (or sesquiterpenes) are administered alone or in combination with radiation, surgery, or chemotherapeutic agents. The monoterpenes or sesquiterpenes can be co-administered with antiviral agents, anti-inflammatory agents, or antibiotics. The substances can be administered simultaneously or sequentially.
[0119] The present invention also provides a method for inhibiting cell proliferation in vitro, ex vivo, or in vivo, wherein cells, such as cancer cells, are contacted with an effective amount of the purified monoterpene (or sesquiterpene) described herein.The compositions and methods of the present invention can be used to inhibit the proliferation of cells that are resistant to chemotherapeutic agents.For example, the compositions and methods of the present invention can be used to inhibit the proliferation of temozolomide-resistant cells.
[0120] Pathological cells or tissues, such as hyperproliferative cells or tissues, can be treated by contacting the cells or tissues with an effective amount of the compositions of the present invention. Cells, such as cancer cells, can be primary cancer cells or cultured cells available from tissue banks such as the American Type Culture Collection (ATCC). Pathological cells can be cells of systemic cancer, glioma, meningioma, pituitary adenoma, or CNS metastases from systemic cancer, lung cancer, prostate cancer, breast cancer, hematopoietic cancer, or ovarian cancer. Cells can be derived from vertebrates, preferably mammals, and more preferably humans. U.S. Patent Publication No. 2004 / 0087651; Balassiano et al. (2002) Intern. J. Mol. Med. 10:785-788; Thorne et al. (2004) Neuroscience 127:481-496; Fernandes et al. (2005) Oncology Reports 13:943-947; Da Fonseca et al. (2008) Surgical Neurology 70:259267; Da Fonseca et al. (2008) Arch. Immunol. Ther. Exp. 56:267-276; Hashizume et al. (2008) Neuroncology 10:112-120.
[0121] Cancer stem cells (CSCs), or tumor-initiating cells, are immature cells that possess stem cell characteristics, such as self-renewal. However, self-renewal is impaired in CSCs. Reya et al., Stem cells, cancer, and cancer stem cells. Nature. 2001, 414(6859):105-11. Glioma CSCs are also resistant to chemotherapy and radiotherapy. Bao et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006, 444(7120):756-60; Rich et al., Chemotherapy and cancer stem cells. Cell Stem Cell. 2007;1(4):353-5. The present compositions and methods can be used to inhibit the proliferation of cancer stem cells, including, but not limited to, glioblastoma cancer stem cells.
[0122] The in vitro efficacy of the composition can be determined using methods well known in the art. For example, the cytotoxicity of the monoterpene (or sesquiterpene) and / or therapeutic agent can be tested by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cytotoxicity assay. The MTT assay is based on the principle of uptake of the tetrazolium salt MTT by metabolically active cells, where it is metabolized to a blue formazon product that can be read spectrophotometrically. J. of Immunological Methods 65:55 63, 1983. The cytotoxicity of the monoterpene (or sesquiterpene) and / or therapeutic agent can be tested by colony formation assay. Functional assays for the inhibition of VEGF secretion and IL-8 secretion can be performed by ELISA. Cell cycle blockade by the monoterpene (or sesquiterpene) and / or therapeutic agent can be tested by standard propidium iodide (PI) staining and flow cytometry. Invasion inhibition can be tested using a Boyden chamber. In this assay, Matrigel, a layer of reconstituted basement membrane, is coated onto a chemotactic filter and acts as a barrier to cell migration within the Boyden chamber. Only cells with invasive potential can pass through the Matrigel barrier. Other assays include, but are not limited to, cell viability assays, apoptosis assays, and morphological assays.
[0123] The following examples are offered for illustrative purposes only and are not intended to limit the invention.
[0124] Example 1: Purification of (S)-perillyl alcohol via 3,5-dinitrobenzoic acid ester (S)-Perillyl alcohol can be purified directly from natural products or obtained by synthetic modification of natural products such as beta-pinene (extracted from pine trees) by oxidation and rearrangement (Scheme 1). [ka]
[0125] Such sources of (S)-perillyl alcohol are inevitably contaminated with isomers of the target compound, which are very similar in physicochemical properties and therefore difficult to remove by conventional purification methods such as fractional distillation or chromatography.
[0126] In this example, to purify (S)-perillyl alcohol from contaminants typically associated with it from natural and / or synthetic sources, perillyl alcohol was first derivatized as its 3,5-dinitrobenzoate ester, which was then separated from the contaminants by conventional crystallization. Once the derivatized (S)-perillyl alcohol was purified by crystallization, it could be hydrolyzed to recover purified (S)-perillyl alcohol (Scheme 2). The purified (S)-perillyl alcohol thus produced has a purity of greater than about 99%. [ka]
[0127] Synthesis of 3,5-dinitrobenzoic acid 4-(S)-isopropenylcyclohex-1-enylmethyl ester (compound 3) Triethylamine (12.2 mL, 87.5 mmol) was added over 0.25 h to a mixture of (S)-perillyl alcohol (1, 89.5%, 10.0 g, 58.7 mmol) in dichloromethane (70 mL), maintaining the temperature below 15° C. The reaction mixture was stirred at room temperature for 30 min. A solution of 3,5-dinitrobenzoyl chloride (compound 2, 14.23 g, 61.7 mmol) dissolved in dichloromethane (30 mL) was added over 0.5 h, maintaining the temperature below 15° C. The reaction mixture was allowed to warm to room temperature and then stirred for 3.0 h. The reaction mixture was quenched with water (75 mL), and the organic layer was separated. The aqueous layer was extracted with dichloromethane (50 mL). The combined organic layers were washed with water (2×100 mL) and dried over sodium sulfate (25 g). The filtered organic layer was concentrated, and the resulting residue was crystallized from diisopropyl ether (200 mL) to give pure compound 3 (weight: 14.45 g). The mother liquor was concentrated to half its volume to give 2.1 g as a second crop (total yield: 81.2%, purity: 99.4% by HPLC).
[0128] Hydrolysis of 3,5-dinitrobenzoic acid 4-(S)-isopropenylcyclohex-1-enylmethyl ester (compound 3) Aqueous sodium hydroxide (3.23 g, 80.0 mmol, dissolved in 28 mL of water) was added to an ice-cold solution of 3,5-dinitrobenzoic acid 4-isopropenyl-cyclohex-1-enylmethyl ester (14.0 g, 40.4 mmol) in methanol (140 mL) over 0.25 h. The reaction mixture was allowed to warm to room temperature and then stirred for 3.0 h. The methanol was concentrated in vacuo, and the resulting residue was suspended in water (60 mL) and extracted with ethyl acetate (2 × 100 mL). The organic layer was washed with water (2 × 100 mL), then brine (15%, 100 mL), and dried over sodium sulfate (30 g). The filtered organic layer was concentrated in vacuo to give pure (S)-perillyl alcohol (weight: 5.84 g, yield: 95%, purity: 99.4% by GC).
[0129] Example 2: Synthesis of 3,5-dinitrobenzoic acid 4(S)-isopropenylcyclohex-1-enylmethyl ester (compound 3) and purification by preparative chromatography Triethylamine (5.3 mL, 38.0 mmol) was added over 0.25 h to a mixture of (S)-perillyl alcohol (89.5%, 5.0 g, 29.3 mmol) in dichloromethane (40 mL), maintaining the temperature below 15 °C. The reaction mixture was stirred at room temperature for 30 min. A solution of 3,5-dinitrobenzoyl chloride (7.43 g, 32.2 mmol) in dichloromethane (15 mL) was added over 0.5 h, maintaining the temperature between 15 and 20 °C. The reaction mixture was allowed to warm to room temperature and then stirred for 3.0 h. The reaction mixture was quenched with water (40 mL), and the organic layer was separated. The aqueous layer was extracted with dichloromethane (25 mL). The combined organic layers were washed with water (2 × 50 mL) and dried over sodium sulfate (20 g). The filtered organic layer was concentrated in vacuo to give a residue that was purified by column chromatography. The column dimensions were as follows: diameter: 2.5 cm, height: 30 cm, silica: 200 mesh. The column was eluted with hexane:ethyl acetate (98:2, 200 mL), followed by hexane:ethyl acetate (95:5). Based on TLC analysis of the fractions (solvent system: hexane:ethyl acetate (90:10)), the hexane:ethyl acetate (95:5) fractions were combined and concentrated under vacuum to give a solid (weight: 7.9 g, yield: 78%).
[0130] Example 2: Synthesis of 4-nitrobenzoic acid 4(S)-isopropenylcyclohex-1-enylmethyl ester (Scheme 3) [ka]
[0131] Triethylamine (5.92 mL, 42.4 mmol) was added over 0.25 h to a mixture of (S)-perillyl alcohol (5.0 g, 32.8 mmol) in dichloromethane (30 mL), maintaining the temperature below 15° C. The reaction mixture was stirred at room temperature for 30 min. A solution of 4-nitrobenzoyl chloride (6.39 g, 34.4 mmol) in dichloromethane (30 mL) was added over 0.5 h, maintaining the temperature below 15° C. The reaction mixture was allowed to warm to room temperature and then stirred for 3.0 h. The reaction mixture was quenched with water (50 mL), and the organic layer was separated. The aqueous layer was extracted with dichloromethane (25 mL). The combined organic layers were washed with water (2×50 mL) and dried over sodium sulfate (20 g). The filtered organic layer was concentrated to give an oil (weight: 8.9 g, yield: 90%).
[0132] Example 3: Synthesis of 4-chlorobenzoic acid 4(S)-isopropenylcyclohex-1-enylmethyl ester (Scheme 4) [ka]
[0133] Triethylamine (2.85 mL, 20.5 mmol) was added over 0.25 h to a mixture of (S)-perillyl alcohol (2.5 g, 16.4 mmol) in dichloromethane (25 mL), maintaining the temperature below 15° C. The reaction mixture was stirred at room temperature for 30 min. A solution of 4-chlorobenzoyl chloride (3.01 g, 17.2 mmol) in dichloromethane (10 mL) was added over 0.5 h, maintaining the temperature below 15° C. The reaction mixture was allowed to warm to room temperature and then stirred for 3.0 h. The reaction mixture was quenched with water (30 mL), and the organic layer was separated. The aqueous layer was extracted with dichloromethane (25 mL). The combined organic layers were washed with water (2×30 mL) and dried over sodium sulfate (15 g). The filtered organic layer was concentrated to give an oil (weight: 3.8 g, yield: 81.7%).
[0134] Example 4: Synthesis of 3,4,5-trimethoxybenzoic acid 4(S)-isopropenylcyclohex-1-enylmethyl ester (Scheme 5) [ka]
[0135] Triethylamine (2.85 mL, 20.5 mmol) was added over 0.25 h to a mixture of (S)-perillyl alcohol (2.5 g, 16.4 mmol) in dichloromethane (25 mL), maintaining the temperature below 15° C. The reaction mixture was stirred at room temperature for 30 min. A solution of 3,4,5-trimethoxybenzoyl chloride (3.97 g, 17.2 mmol) in dichloromethane (10 mL) was added over 0.5 h, maintaining the temperature below 15° C. The reaction mixture was allowed to warm to room temperature and then stirred for 3.0 h. The reaction mixture was quenched with water (30 mL), and the organic layer was separated. The aqueous layer was extracted with dichloromethane (25 mL). The combined organic layers were washed with water (2×30 mL) and dried over sodium sulfate (15 g). The filtered organic layer was concentrated to give an oil (weight: 4.8 g, yield: 84.6%).
[0136] Example 5: Synthesis of 4-trimethoxybenzoic acid 4(S)-isopropenylcyclohex-1-enylmethyl ester (Scheme 6) [ka]
[0137] Triethylamine (2.97 mL, 21.3 mmol) was added over 0.25 h to a mixture of (S)-perillyl alcohol (2.5 g, 16.4 mmol) in dichloromethane (25 mL), maintaining the temperature below 15° C. The reaction mixture was stirred at room temperature for 30 min. A solution of 4-methoxybenzoyl chloride (2.94 g, 17.2 mmol) in dichloromethane (10 mL) was added over 0.5 h, maintaining the temperature below 15° C. The reaction mixture was allowed to warm to room temperature and then stirred for 3.0 h. The reaction mixture was quenched with water (30 mL), and the organic layer was separated. The aqueous layer was extracted with dichloromethane (25 mL). The combined organic layers were washed with water (2×30 mL) and dried over sodium sulfate (15 g). The filtered organic layer was concentrated to give an oil (weight: 4.1 g, yield: 87%).
[0138] Example 6: Synthesis of dimethyl celecoxib bis POH carbamate (4-(bis-N,N'-4-isopropenylcyclohex-1-enylmethyloxycarbonyl[5-(2,5-dimethylphenyl)-3-trifluoromethylpyrazol-1-yl]benzenesulfonamide) The reaction scheme is as follows: [ka]
[0139] Phosgene (20% in toluene, 13 mL, 26.2 mmol) was added over 30 hours to a mixture of perillyl alcohol (2.0 grams, 13.1 mmol) and potassium carbonate (5.4 grams, 39.1 mmol) in dry toluene (30 mL), maintaining the temperature between 10 and 15°C. The reaction mixture was warmed to room temperature and stirred under N2 for 8 hours. The reaction mixture was quenched with water (30 mL), and the organic layer was separated. The aqueous layer was extracted with toluene (20 mL), and the combined organic layers were washed with water (50 mL x 2), brine (15%, 30 mL), and dried over sodium sulfate (20 grams). The filtered organic layer was concentrated under vacuum to give perillyl chloroformate as an oil. Weight: 2.5 grams; Yield: 89%. 1H-NMR (400MHz, CDCl3): δ 1.5 (m, 1H), 1.7 (s, 3H), 1.8 (m, 1H), 2.0 (m, 1H), 2.2 (m, 4H), 4.7 (dd, 4H); 5.87 (m, 1H).
[0140] Perillyl chloroformate (0.11 grams, 0.55 mmol) was added slowly over 5 minutes to a mixture of dimethyl celecoxib (0.2 grams, 0.50 mmol) and potassium carbonate (0.13 grams, 1.0 mmol) in dry acetone (10 mL) under N2. The reaction mixture was heated to reflux and maintained for 3 hours. TLC analysis indicated the presence of dimethyl celecoxib (>60%), so an additional 1.0 equivalent of perillyl chloroformate was added and refluxed for an additional 5 hours. The reaction mixture was cooled, and the acetone was concentrated under vacuum to provide a residue.
[0141] The resulting residue was suspended in water (15 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with water (20 mL), then brine (15%, 20 mL), and dried over sodium sulfate. The filtered organic layer was concentrated in vacuo to give a residue, which was purified by column chromatography [column dimensions: diameter: 1.5 cm, height: 10 cm, silica: 230-400 mesh] eluting with hexane (100 mL) and then a mixture of hexane / ethyl acetate (95:5, 100 mL). The hexane / ethyl acetate fractions were combined and concentrated in vacuo to give a gummy mass.
[0142] The product POH carbamate weighed 120 mg and gave a yield of 31%. 1 H-NMR (400MHz, CDCl3): δ 0.9(m,2H),1.4(m,2H),1.7(m,7H * ), 1.95(m,8H * ),2.1(m,4H),2.3(s,3H),4.4(d,2H),4.7(dd,2H),5.6(br d,2H),6.6(s,1H),7.0(br s,1H),7.12(d,1H),7.19(d,1H),7.4(d,2H),7.85(d,2H);MS,m / e:751.8(M +3%), 574.3(100%), 530.5(45%), 396(6%). * Note: Additional 2H overlap from putative impurities has been ignored in the NMR integration.
[0143] Example 7: Synthesis of temozolomide POH carbamate (3-methyl 4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl)-carbamic acid-4-isopropenylcyclohex-1-enylmethyl ester) The reaction scheme is as follows: [ka]
[0144] Oxalyl chloride (0.13 grams, 1.0 mmol) was added slowly over 2 minutes to a mixture of temozolomide (OChem Incorporation, 0.1 grams, 0.5 mmol) in 1,2-dichloroethane (10 mL) while maintaining the temperature at 10°C under N2. The reaction mixture was allowed to warm to room temperature and then heated to reflux for 3 hours. Excess oxalyl chloride and 1,2-dichloroethane were removed by concentration under vacuum. The resulting residue was redissolved in 1,2-dichloroethane (15 mL), and the reaction mixture was cooled to 10°C under N2. A solution of perillyl alcohol (0.086 grams, 0.56 mmol) in 1,2-dichloroethane (3 mL) was added over 5 minutes. The reaction mixture was allowed to warm to room temperature and stirred for 14 hours. The 1,2-dichloroethane was concentrated under vacuum to give a residue that was triturated with hexane. The resulting yellow solid was filtered and washed with hexane. Weight: 170 mg; Yield: 89%. 1 H-NMR (400 MHz, CDCl): δ 1.4-2.2 (m, 10H), 4.06 (s, 3H), 4.6-4.8 (m, 4H), 5.88 (br s, 1H), 8.42 (s, 1H), 9.31 (br s, 1H); MS, no molecular ion peak observed. m / e: 314 (100%), 286.5 (17%), 136 (12%).
[0145] Alternatively, temozolomide POH carbamate was synthesized according to the following procedure. Oxalyl chloride (0.13 grams, 1.0 mmol) was added slowly over 2 minutes to a mixture of temozolomide (OChem Incorporation, 0.1 grams, 0.5 mmol) in 1,2-dichloroethane (10 mL) while maintaining the temperature at 10° C. under N2. The reaction mixture was allowed to warm to room temperature and then heated to reflux for 3 hours. Excess oxalyl chloride and 1,2-dichloroethane were removed by concentration under vacuum. The resulting residue was redissolved in 1,2-dichloroethane (15 mL), and the reaction mixture was cooled to 10° C. under N2. A solution of perillyl alcohol (0.086 grams, 0.56 mmol) in 1,2-dichloroethane (3 mL) was added over 5 minutes. The reaction mixture was allowed to warm to room temperature and stirred for 14 hours. The 1,2-dichloroethane was concentrated under vacuum to give a residue, which was purified by a short silica plug column (column dimensions: diameter: 2 cm, height: 3 cm, silica: 230-400 mesh) and eluted with a mixture of hexane / ethyl acetate (1:1, 100 mL). The hexane / ethyl acetate fractions were combined and concentrated under vacuum to give a white solid residue, which was triturated with heptane and filtered to give a white solid. Weight: 170 mg; Yield: 89%. 1 H-NMR (400 MHz, CDCl): 1.4-2.2 (m, 10H), 4.06 (s, 3H), 4.6-4.8 (m, 4H), 5.88 (br s, 1H), 8.42 (s, 1H), 9.31 (br s, 1H); MS, no molecular ion peak observed; m / e: 314 (100%), 286.5 (17%), 136 (12%).
[0146] Example 8: Synthesis of rolipram POH carbamate (4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxo-pyrrolidine-1-carboxylic acid 4-isopropenylcyclohex-1-enylmethyl ester) [ka]
[0147] Phosgene (20% in toluene, 13 mL, 26.2 mmol) was added over 30 hours to a mixture of perillyl alcohol (2.0 grams, 13.1 mmol) and potassium carbonate (5.4 grams, 39.1 mmol) in dry toluene (30 mL), maintaining the temperature between 10 and 15°C. The reaction mixture was warmed to room temperature and stirred under N2 for 8 hours. The reaction mixture was quenched with water (30 mL), and the organic layer was separated. The aqueous layer was extracted with toluene (20 mL), and the combined organic layers were washed with water (50 mL x 2), brine (15%, 30 mL), and dried over sodium sulfate (20 grams). The filtered organic layer was concentrated under vacuum to give perillyl chloroformate as an oil. Weight: 2.5 grams; Yield: 89%. 1 H-NMR (400MHz, CDCl3): δ 1.5 (m, 1H), 1.7 (s, 3H), 1.8 (m, 1H), 2.0 (m, 1H), 2.2 (m, 4H), 4.7 (dd, 4H); 5.87 (m, 1H).
[0148] Butyllithium (2.5 M, 0.18 mL, 0.45 mmol) was added to rolipram (GL synthesis, Inc., 0.1 gram, 0.36 mmol) in dry THF at -72°C under N2 over 5 minutes. The reaction mixture was stirred at -72°C for 1.0 hour, after which perillyl chloroformate (dissolved in 4 mL of THF) was added over 15 minutes while maintaining the temperature at -72°C. The reaction mixture was stirred for 2.5 hours and quenched with saturated ammonium chloride (5 mL). The reaction mixture was warmed to room temperature and extracted with ethyl acetate (2 x 15 mL). The combined organic layers were washed with water (15 mL), brine (15%, 15 mL), and then dried over sodium sulfate. The filtered organic layer was concentrated to give an oil, which was purified by column chromatography [Column dimensions: diameter: 1.5 cm, height: 10 cm, silica: 230-400 mesh], eluting with a mixture of 8% ethyl acetate / hexane (100 mL) followed by 12% ethyl acetate / hexane (100 mL). The 12% ethyl acetate / hexane fractions were combined and concentrated under vacuum to give a gummy solid. Weight: 142 mg; Yield: 86%. 1H-NMR(400MHz, CDCl3):δ 1.5(m,1H),1.6(m,2H),1.7(s,3H),1.9(m,6H),2.2(m,5H),2.7(m,1H),2.9 (m,1H),3.5(m,1H),3.7(m,1H),3.8(s,3H),4.2(m,1H),4.7(m,6H),5.8(br s,1H),6.8(m,3H);MS,m / e:452.1(M+1 53%),274.1(100%),206.0(55%).
[0149] Example 9: Treatment of recurrent glioblastoma with perillyl alcohol There is an urgent need for better treatments for patients with glioblastoma (GBM), especially those with recurrent disease. Clinical trials conducted in Brazil have shown that intranasal delivery of perillyl alcohol (POH) may be effective in this patient population. To evaluate the safety and efficacy of this novel approach in a Phase 1 / 2a clinical trial in the United States, a highly purified form of POH, NEO100, was manufactured under cGMP.
[0150] This study presents results from a completed Phase 1 study using intranasal NEO100 in patients with recurrent glioblastoma (GBM). NEO100 is a highly purified, cGMP-manufactured form of the natural monoterpene perillyl alcohol. Our results demonstrate that intranasal NEO100 is safe and can be used to treat recurrent glioblastoma. The historical survival time for first-time recurrent GBM in IDH1 wild-type patients was 9.8 months, while the survival time for first-time recurrent GBM in IDH1 mutant patients was 19.32 months. No increase in progression-free survival was observed (Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, DeGroot JF: Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol 129:147-154, 2016). Treatment with NEO100 in IDH1-mutated recurrent GBM resulted in unexpectedly long progression-free survival (mean 32 months) and overall survival (all still alive, mean 32 months) in three patients.
[0151] A total of 12 patients with recurrent GBM were enrolled in the first phase of this clinical trial. NEO100 was administered via intranasal delivery using a nebulizer and nasal mask. Administration was four times daily. Four cohorts of three patients received the following doses: 96 mg / dose (384 mg / day), 144 mg / dose (576 mg / day), 192 mg / dose (768 mg / day), and 288 mg / dose (1152 mg / day). A completed 28-day treatment cycle was recorded. Adverse events were recorded, and radiographic response according to the RANO criteria was assessed every two months. Progression-free survival and overall survival were measured at 6 and 12 months, respectively (PFS-6, OS-12).
[0152] Intranasal NEO100 was well tolerated at all dose levels, with no serious adverse events reported. PFS-6 was 33%, OS-12 was 55%, and median OS was 15 months. Four patients (33%) survived for more than 24 months.
[0153] Intranasal glioma treatment with NEO100 was well tolerated and correlated with improved survival when compared with historical controls, indicating that this novel intranasal approach may be useful for treating recurrent GBM.
[0154] The prognosis for patients with recurrent glioblastoma remains dismal, and better treatment options are urgently needed. Our phase 1 study evaluated intranasal administration of NEO100, a highly purified form of perillyl alcohol, a natural limonene-related compound, as a potential novel treatment for this patient population. Patients with recurrent glioblastoma self-administered NEO100 via nebulizer four times daily. NEO100 had an excellent safety profile and suggestive evidence of activity. Intranasal NEO100 represents a novel approach to brain tumor treatment and may be clinically useful for improving outcomes for patients with recurrent glioblastoma.
[0155] Introduction Glioblastoma (GBM; WHO grade IV glioma) is the most common primary malignant brain tumor among adults. Regardless of treatment regimen, the majority of patients relapse and face limited treatment options. The aggressive infiltration of GBM throughout the brain typically limits the effectiveness of repeated surgical resections, and tumor cells often acquire resistance to further cytotoxic therapies. Thus, recurrent GBM does not respond adequately to repeated surgeries, re-irradiation, and additional rounds of chemotherapy. Although these interventions can modestly extend overall survival, the prognosis for these patients remains extremely poor. In the United States and Canada, the angiogenesis inhibitor bevacizumab has received market approval for the treatment of recurrent GBM. 2It is a humanized monoclonal antibody against VEGF (vascular endothelial growth factor) and therefore represents a targeted therapy. It can be used alone or in combination with cytotoxic chemotherapy. However, the duration of benefit is short and its impact on overall survival remains limited and uninspiring. This is the main reason why it has not been approved by European authorities. 3 .
[0156] Given the persistent medical need for improved treatments, we are investigating a novel type of intervention: intranasal delivery of perillyl alcohol (NEO100) for patients with recurrent GBM. POH (also called p-meta-1,7-dien-6-ol) is a monoterpene isolated from the essential oils of lavender, citrus fruits, peppermint, and several other plants that synthesize it via the mevalonate pathway. 4 Extensive preclinical studies have provided strong evidence for the anticancer activity of this natural compound. The exact mechanism of POH's anticancer effects is unclear, but it likely results from pleiotropic effects, including induction of cell cycle arrest, endoplasmic reticulum stress, and apoptosis. 5 .
[0157] POH has been shown to inhibit the enzymatic activity of farnesyl protein transferase (FPT) in the mevalonate pathway, and thus POH inhibits the oncogenic activity of Ras proteins, which require posttranslational farnesylation for plasma membrane anchoring and mitogenic activity. 6 It has been hypothesized that POH may cause the suppression of Ras. However, several studies in this regard have shown inconclusive and equivocal results. Perhaps any effect on Ras activity is only one of several mechanisms by which POH exerts its anticancer effects (see detailed references). 5(See ). Despite consistent anticancer activity in various preclinical models, numerous Phase 1 and Phase 2 trials in the late 1990s in patients with various solid tumors failed to demonstrate convincing therapeutic activity. In these studies, POH was formulated in gelatin capsules and administered orally at fairly large doses of several grams three to four times daily. Gastrointestinal toxicity proved dose-limiting, and some patients discontinued the trials due to severe chronic fatigue (fatigue, nausea, belching, reflux, diarrhea, or constipation). 7,9 As a result, oral POH was abandoned and not introduced into clinical practice.
[0158] Nasal delivery of chemotherapy is envisioned as a novel, paradigm-shifting platform for delivering therapeutic agents to the brain while minimizing systemic toxicity and first-pass metabolism. 10,12 Effective nose-to-brain delivery has been demonstrated in a variety of non-cancer conditions, such as migraines, stroke, and other neurological conditions. 9,13 For example, intranasal insulin has been shown to improve cognition in early Alzheimer's disease 14,15 Although not yet fully characterized, the putative mechanism of drug uptake in the brain is thought to involve the olfactory and trigeminal nerves and the nasal mucosa. These factors combined facilitate direct access and rapid absorption of drugs, thereby resulting in greater bioavailability and a rapid onset of drug response. 13,16,17 However, despite these clear advantages, nasal delivery of cancer therapeutics has not been established in clinical practice.
[0159] A phase 2 study conducted in Brazil in patients with recurrent malignant glioma pioneered intranasal delivery of POH as a novel paradigm for cancer treatment. Commercial-grade POH was self-administered four times daily. Several published reports from these studies indicated that this alternative drug delivery method has the potential to provide activity in this patient population. 18,20Furthermore, it was well tolerated without any long-term CNS or systemic serious adverse events, and patient compliance was reportedly very high (>95%). 20 Radiographic regression was reported. 19,20 .
[0160] We set out to investigate the clinical safety and activity of intranasal NEO100, a highly purified form of POH manufactured under current Good Manufacturing Practice (cGMP) conditions, in patients with recurrent GBM. A Phase 1 / 2a trial is currently underway, and we report here the results from the completed Phase 1 portion.
[0161] 2. Patients and methods Phase 1 clinical trial The ongoing interventional clinical trial titled "An Open-Label, Phase 1 / 2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma" [ClinicalTrials.gov Identifier: NCT02704858] is a multicenter trial. Participating centers include Cleveland Clinic, University of Washington / Seattle, University of Wisconsin, and University of Southern California. It is sponsored by NeOnc Technologies, Inc. (Los Angeles, CA), with ClinDatrix, Inc. (Irvine, CA) as the clinical data management CRO. Patients were enrolled according to a protocol approved by the institutional review board (IRB) and after signing the appropriate informed consent form approved by the IRS. For the Phase 1 portion of this trial, the first patient was enrolled in April 2017, and the 12th patient was enrolled in June 2019. The primary objectives of Phase 1 were: (i) to determine the safety and tolerability of intranasal administration of NEO100, and (ii) to identify the maximum tolerated dose of NEO100.
[0162] Administration of NEO100 - NEO100 is highly purified perillyl alcohol manufactured under cGMP conditions at Norac Pharma (Azusa, CA). It is delivered intranasally using a nebulizer and nasal mask four times daily. After initial hands-on training and explanations by a clinic nurse, patients self-administer each dose. NEO100 is provided to each patient formulated as a 10% stock solution in ethanol:glycerol (50:50, v / v). Before each use, the stock solution is diluted with water and loaded into the nebulizer.
[0163] Key Inclusion Criteria - Inclusion criteria included: (i) radiographically confirmed progressive or recurrent grade IV glioma; and stable doses of steroids for at least 5 days. (ii) Patients were likely to have failed previous radiation and temozolomide treatments. (iii) 18 years of age. (iv) KPS 600 or ECOG activity index of 0-2. (v) expected survival of at least 3 months. (vi) baseline MRI with gadolinium within 2 weeks of study entry. (vii) seizure control with stable doses of antiepileptic medication for 2 weeks prior to enrollment.
[0164] Response Assessment - Patients will undergo gadolinium-enhanced brain MRI as part of standard of care. Baseline tumor measurements will be performed within 2 weeks of enrollment and assessed by RANO (Response Assessment in Neuro-Oncology) criteria. MRI will be repeated after each even-numbered cycle (i.e., cycles 2, 4, and 6) for 28 days and whenever disease progression is suspected based on clinical symptoms. Tumor response will be assessed using both the MacDonald and RANO response criteria for high-grade glioma, which consider radiological imaging, neurological status, and steroid administration. Safety will be assessed throughout the study by the occurrence of adverse events (AEs), physical examination findings, vital signs, and laboratory results. NCI Common Terminology Criteria for Adverse Events v.4.0 21The AEs are graded for severity using the Scale.
[0165] result Presented here are the completed phase 1 results of an ongoing phase 1 / 2a study of intranasally administered NEO100 in patients with recurrent GBM after failure of standard chemoradiotherapy with temozolomide. Twelve patients were enrolled (demographics and baseline characteristics are shown in Table 1). Sequential cohorts of three patients each received intranasal NEO100 at escalating doses of 384 mg / day, 576 mg / day, 768 mg / day, and 1152 mg / day. Patients self-administered these doses, divided into four equal doses, approximately 5-6 hours apart daily.
[0166] No severe (grade 3 or 4) adverse events were observed in any of the cohorts during any of the monthly cycles. Other adverse events (grade 1) consisted of nasal pain or itching, runny nose, peri-nasal skin irritation, or headache. One patient in cohort 2 experienced recurrent grade 2 leukopenia, but the causal relationship to NEO100 treatment was unknown (Table 2).
[0167] NEO100 treatment was initially planned as a continuous 6-month treatment. Patients with stable disease at 6 months were able to continue treatment under the extended use protocol, while patients who progressed early discontinued treatment. Progression-free survival rates for the first 6 months are summarized in Figure 1 and Table 3. As shown, patients in Cohort 1 (the lowest dose) completed only two cycles (i.e., 2 months) of NEO100 treatment because progressive disease was observed at the end of these cycles. In Cohort 2, two patients also experienced early progressive disease (after cycles 1 and 2), but the third patient (identification number 202) had stable disease at 6 months and has continued to receive NEO100 for a total of 33 cycles to date. Her tumor shrank by more than 75% as measured by MRI. In Cohort 3, only one patient terminated treatment early due to progressive disease, while the other two patients remained stable at 6 months and therefore continued treatment. One of these two patients (identifier 302) completed 11 cycles and then went an additional 16 months without NEO100 treatment, and is still alive. The other patient (identifier 301) has continued a total of 24 cycles of treatment and is still alive. This patient also achieved radiographic complete remission, which has continued to the present. In cohort 4, two patients did not complete the full 6 months of treatment due to progression at 2 and 4 months, respectively. One of these patients (identifier 402) survived an additional 13 months after discontinuing NEO100. Another patient (identifier 401) was lost to follow-up immediately after completing four cycles, and his current status is unknown. The third patient in this cohort (identifier 403) had stable disease at 6 months, but then rapidly deteriorated and died 3 months later. Overall, the PFS-6 across the entire group of patients (n = 12) enrolled in this phase 1 study was 33%, with cohort 1 showing the lowest PFS-6 (0%) and cohort 3 showing the highest PFS-6 (67%) (Figure 1).
[0168] Examples of radiographic responses are shown in Figure 2, which shows a partial response after 10 months of NEO100 treatment and a complete response after 12 months of NEO100 treatment. Overall survival at 12 months (OS-12) was 55% and at 24 months (OS-24) was 37%, with a median OS of 15 months.
[0169] (Figure 3A). Overall, several patients experienced significantly longer survival times. Four patients survived for at least 24 months, three of whom are still alive (Table 3). Thus, despite a PFS-6 rate of only 33%, the median OS of 15 months was encouraging. For further analysis, all patients were divided into two groups: those who completed at least six cycles of NEO100 (n = 4) and those who did not (n = ?). The latter group included one patient who completed one cycle, six patients who completed two cycles, and one patient who completed four cycles (this patient was lost to follow-up immediately after completing four cycles and was therefore excluded from comparison).
[0170] Interestingly, there was a notable difference in long-term survival between these two groups, although it did not reach statistical significance. As shown in Figure 3B, in the four patients who completed at least six cycles, OS-24 was 75%. By comparison, in the six evaluable patients who completed only one or two cycles, OS-24 was 14%. However, despite the poorer outcome in this second group compared with the first, the median OS was a remarkable 11 months, again demonstrating that long-term survival is very promising despite early progression.
[0171] We also analyzed overall survival based on the status of the isocitrate dehydrogenase 1 (IDH1) gene. Mutations at amino acid 132 of IDH1 are present in more than 70% of grade II and III astrocytomas and oligodendrogliomas, as well as glioblastomas arising from these lesions. See N. England J. Med. 2009;360:765-773. IDH1 / IDH2 mutation analysis can be performed as part of a standard clinical testing protocol using SNaPshot Multiplex PCR (polymerase chain reaction). See, e.g., https: / / www.labcorp.com / tests / 481484 / i-idh1-idh2-i-mutation-analysis (retrieved 11 / 11 / 2021), https: / / www.mayocliniclabs.com / test-catalog / Clinical+and+Interpretive / 92361 (retrieved 11 / 11 / 2021), and https: / / www.mdanderson.org / research / research-resources / core-facilities / molecular-diagnostics-lab / services / idh1-mutation-analysis.html (retrieved 11 / 11 / 2021). Mutations in this gene are known to confer a survival advantage in newly diagnosed glioma patients. 22As shown in Figure 3C, patients with IDH1-mutated tumors experienced significantly longer overall survival (p = 0.018), with 4 of 5 (80%) patients surviving at least 24 months. In comparison, none of the patients with wild-type IDH1 survived beyond 18 months, yet the median OS was a remarkable 11 months. The presence of perillic acid (PA) was measured in plasma obtained from all patients at various time points after the first daily dose of intranasal NEO100. These blood draws were performed on days 1 and 8 of the first 28-day cycle and repeated on day 1 of the second cycle. PA is the major metabolite of perillyl alcohol and is more stable, thus providing a convenient and easily detectable marker of POH exposure. As shown in Figure 4, plasma concentrations of PA were readily quantifiable, with maximum concentrations present 5 minutes after NEO100 administration and an initial half-life of approximately 20 minutes. The mean maximum plasma PA concentrations were higher in patients receiving the higher dose. Additionally, within each cohort, these concentrations were significantly higher over the following 2 days compared with measurements taken on the first dose (Cycle 1, Day 1). Despite significant interpatient variability in absolute values, Cmax decreased by >90% in most patients within 2 hours after intranasal delivery. Overall, these data demonstrated rapid entry of drug into the systemic circulation, followed by first-order elimination kinetics and a lack of accumulation.
[0172] Consideration This study provides evidence that intranasal NEO100, when administered four times daily, is safe and potentially effective in patients with recurrent GBM. The treatment was well tolerated at all dose levels, and no serious adverse events were reported. The MTD was not reached at the highest dose used (1152 mg / day divided into four equal doses of 288 mg). These results are consistent with those obtained in a Brazilian phase 1 / 2 study using commercial-grade NEO100 in patients with recurrent GBM, grade III anaplastic astrocytoma, and anaplastic oligodendroglioma, albeit at a lower dose of 133 mg qid (534 mg / day). 18,20In those studies, compliance with the protocol was high (>95%), and although nasal soreness was occasionally noted, no serious side effects were observed, even after several years of continuous application.
[0173] Despite the small number of patients in our current study, initial analyses of the efficacy of intranasal NEO100 in patients with recurrent GBM appear promising. PFS-6 was 33%, OS-6 was 92%, OS-12 was 58%, and four patients (33%) survived for more than 24 months. This compares very favorably with previous single-agent studies in patients with recurrent GBM, some of which are summarized in Supplementary Table 1. Wong et al. reviewed eight phase 2 studies with various treatments conducted in the pre-temozolomide era, which showed a mean OS-12 of 21% and a median OS of 5.7 months. 23 Standard chemoradiation with temozolomide (also known as the Stupp protocol) 4 Several newer studies completed in the past eight years, primarily involving patients who have not responded to previous chemotherapy, have shown mixed results and have only achieved incremental improvements in survival. For example, alternating electric fields (Tumor Treating Fields, TTF, NovoTTF-100A) emerged a decade ago as a conceptually novel approach, but it has not been shown to be as effective as historical controls or conventional chemotherapy, e.g., lomustine. 26 or fotemustine 27 did not demonstrate improved outcomes in the recurrent setting compared with 25 Although bevacizumab has been approved in the United States for the treatment of recurrent GBM, its impact on OS-12 and median OS remains unclear. 28,30 .
[0174] A more recent trial using nivolumab, a fully human monoclonal antibody targeting the programmed death 1 (PD-1) immune checkpoint receptor, also failed to demonstrate substantial improvement, with survival outcomes comparable to those achieved with conventional chemotherapy or bevacizumab. 31 .
[0175] Two recent clinical trials reported median OS results exceeding the target level of 1 year (Supplementary Table 1). One study used Toca-511 (vocimagene amiretrorepvec), a nonlytic retroviral replicating vector carrying yeast cytosine deaminase, which converts separately administered Toca FC (sustained-release 5-fluorocytosine) into the antimetabolite 5-fluorouracil. 32 The trial achieved a median OS of 12% and 13.6 months compared to 55%. Similar results were obtained with direct intratumoral delivery of PVSRIPO, a recombinant poliovirus chimera that recognizes the poliovirus receptor CD155, commonly expressed on the surface of tumor cells. 33 This trial achieved an OS-12 of 54% and a median OS of 12.5 months. Our results with intranasal NEO100 compare very favorably to these improved results, as we achieved an OS-12 of 55% and a median OS of 15 months.
[0176] The key advantages of our study are its very low toxicity, non-invasiveness, and lack of serious adverse events, which highlight that this treatment approach does not reduce the quality of life of patients. In comparison, many of the other treatments mentioned above have suboptimal safety profiles. For example, nitrosoureas are known for their bone marrow suppression, liver / kidney toxicity, or interstitial lung disease, and bevacizumab can cause bleeding and hypertension. Direct administration by convection-enhanced delivery, as in the case of PVSRIPO, is invasive and includes all the risks associated with the placement and removal of surgical catheters. In general, combination regimens have not provided evidence of superior activity and generally result in more significant toxicity. 34 .
[0177] We further made the intriguing observation that even patients who progressed before completing the planned 6 months of treatment with NEO100 lived longer than expected. Upon progression, these patients were switched to the optimal standard treatment combination based on the judgment of their neuro-oncologist. Furthermore, there may have been false progression on MRI scans, leading to early cessation of NEO100. It is important to pay particular attention to these unresolved issues in Part IIa of this study. Another intriguing result was our observation that patients with IDH1 mutations appeared to have a survival advantage. Mutations in the IDH1 gene are a known predictor of better overall survival in malignant gliomas. 22 However, although this association has been firmly established in newly diagnosed patients, it is unclear whether it also applies to the recurrent setting, as inconsistent results (in small numbers of patients) have been reported. For example, Mandel et al. 35 reported that IHD1 mutations can have a positive impact on survival, albeit only at first relapse. However, Tabei et al. 36 Another report by failed to confirm a positive correlation between IDH1 mutations and survival after first progression. Our results for NEO100-treated patients show that patients with IDH1 mutation status survived significantly longer from the time of enrollment in this trial.
[0178] In conclusion, intranasal glioma treatment with NEO100 was well tolerated. It correlated with improved survival compared with historical controls, indicating that this novel approach may be useful for the treatment of recurrent GBM. Its very low toxicity profile may allow for the possibility of combining this regimen with other, more burdensome approaches without increasing adverse events. Furthermore, based on the convenient administration process and ongoing quality of life, patients who progress on intranasal NEO100 may be more inclined to pursue further treatment. Although resistance mechanisms to NEO100 have yet to be identified or characterized, it can be speculated that standard treatments and approaches after progression, listed in Supplementary Table 1, may still provide significant activity and benefit to such patients.
[0179] The scope of the present invention is not limited by what has been particularly shown and described above. Those skilled in the art will recognize that suitable alternatives exist to the illustrated examples in materials, configurations, constructions, and dimensions. Numerous references, including patents and various publications, have been cited and discussed herein. The citation and discussion of such references is provided merely to clarify the description of the present invention, and no reference is admitted to be prior art to the invention described herein. All references cited and discussed herein are incorporated herein by reference in their entirety. Variations, modifications, and other implementations of what is described herein will occur to those skilled in the art without departing from the spirit and scope of the present invention. While specific embodiments of the present invention have been shown and described, it will be apparent to those skilled in the art that changes and modifications can be made without departing from the spirit and scope of the present invention. The matter set forth in the foregoing description and accompanying drawings is set forth solely for purposes of illustration and not limitation.
[0180] References 1. Mehta M,Wen P,Nishikawa R,Reardon D,Peters K.Critical review of the addition of tumor treating fields(TTFields)to the existing standard of care for newly diagnosed glioblastoma patients.Crit Rev Oncol Hematol.2017;111:60-65. 2. Ghiaseddin A,Peters KB.Use of bevacizumab in recurrent glioblastoma.CNS Oncol.2015;4(3):157-169. 3. de Lemos ML,Markarian A,Chan E,Schaff K,Walisser S.Clinical ef- fectiveness of bevacizumab in patients with recurrent brain tumours:a population-based evaluation.J Oncol Pharm Pract.2018;24(1):33-36. 4. Crowell PL,Elson CE.Isoprenoids,health and disease.In:Wildman REC,ed.Nutraceuticals and Functional Foods.Boca Raton,FL:CRC Press;2001:31-54. 5. Chen TC,Fonseca CO,Schonthal AH.Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.Am J Cancer Res.2015;5(5):1580-1593. 6. Gelb MH,Tamanoi F,Yokoyama K,Ghomashchi F,Esson K,Gould MN.The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol.Cancer Lett.1995;91(2):169-175. 7. Bailey HH,Levy D,Harris LSら,A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer:Eastern Cooperative Oncology Group Study E2E96.Gynecol Oncol.2002;85(3):464-468. 8. Liu G,Oettel K,Bailey Hら,Phase II trial of perillyl alcohol(NSC 641066)administered daily in patients with meta- static androgen independent prostate cancer.Invest New Drugs.2003;21(3):367-372. 9. Meadows SM,Mulkerin D,Berlin Jら,Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer.Int J Gastrointest Cancer.2002;32(2-3):125-128. 10. Bitter C,Suter-Zimmermann K,Surber C.Nasal drug delivery in humans. Curr Probl Dermatol.2011;40:20-35. 11. Dhuria SV,Hanson LR,Frey WH II.Intranasal delivery to the central nervous system:mechanisms and experimental considerations.J Pharm Sci.2010;99(4):1654-1673. 12. Peterson A,Bansal A,Hofman F,Chen TC,Zada G.A systematic review of inhaled intranasal therapy for central nervous system neoplasms:an emerging therapeutic option.J Neurooncol.2014;116(3):437-446. 13. Gizurarson S.Anatomical and histological factors affecting intranasal drug and vaccine delivery.Curr Drug Deliv.2012;9(6):566-582. 14. Chapman CD,Schioth HB,Grillo CA,Benedict C.Intranasal insulin in Alzheimer‘s disease:food for thought.Neuropharmacology.2018;136(Pt B):196-201. 15. Reger MA,Watson GS,Green PSら,Intranasal insulin improves cognition and modulates beta-amyloid in early AD.Neurology.2008;70(6):440-448. 16. Illum L.Nasal drug delivery - recent developments and future prospects. J Control Release.2012;161(2):254-263. 17. Ugwoke MI,Agu RU,Verbeke N,Kinget R.Nasal mucoadhesive drug delivery:background,applications,trends and future perspectives.Adv Drug Deliv Rev.2005;57(11):1640-1665. 18. da Fonseca CO,Schwartsmann G,Fischer Jら,Preliminary re- sults from a phase I / II study of perillyl alcohol intranasal admin- istration in adults with recurrent malignant gliomas.Surg Neurol.2008;70(3):259-266. 19. da Fonseca CO,Simao M,Lins IR,Caetano RO,Futuro D,Quirico- Santos T.Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.J Cancer Res Clin Oncol.2011;137(2):287-293. 20. da Fonseca CO,Teixeira RM,Silva JCら,Long-term outcome in pa- tients with recurrent malignant glioma treated with perillyl alcohol inhalation.Anticancer Res.2013;33(12):5625-5631. 21. National Cancer Institute.Common terminology criteria for adverse events(CTCAE)Version 4.0.2009.Accessed August 30,2017. 22. Huang LE.Friend or foe-IDH1 mutations in glioma 10 years on.Carcinogenesis.2019;40(11):1299-1307. 23. Wong ET,Hess KR,Gleason MJら,Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.J Clin Oncol.1999;17(8):2572-2578. 24. Stupp R,Mason WP,van den Bent MJら;Radiotherapy plus concomitant and adjuvant temozolomide for gliobla- toma.N Engl J Med.2005;352(10):987-996. 25. Stupp R,Wong ET,Kanner AAら,NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma:a randomized phase III trial of a novel treatment modality.Eur J Cancer.2012;48(14):2192-2202. [ PubMed ] 26. Batchelor TT,Mulholland P,Neyns Bら,Phase III randomized trial comparing the efficacy of cediranib as monotherapy,and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.J Clin Oncol.2013;31(26):3212-3218. 27. Brandes AA,Finocchiaro G,Zagonel Vら,AVAREG:a phase II,randomized,noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.Neuro Oncol.2016;18(9):1304-1312. 28. Field KM,Simes J,Nowak AKら;CABARET / COGNO investigators.Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.Neuro Oncol.2015;17(11):1504-1513. 29. Heiland DH,Masalha W,Franco P,Machein MR,Weyerbrock A.Progression-free and overall survival in patients with recurrent glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab / lomustine.J Neurooncol.2016;126(3):567-575. 30. Taal W,Oosterkamp HM,Walenkamp AMら,Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma(BELOB trial):a randomised controlled phase 2 trial.Lancet Oncol.2014;15(9):943-953. 31. Reardon DA,Brandes AA,Omuro Aら,Effect of Nivolumab vs bevacizumab in patients with recurrent glioblastoma:The CheckMate 143 Phase 3 randomized clinical trial.JAMA Oncol.2020. 32. Cloughesy TF,Landolfi J,Hogan DJら,Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.Sci Transl Med.2016;8(341):341ra375. 33. Desjardins A,Gromeier M,Herndon JE IIら,Recurrent glioblastoma treated with recombinant poliovirus.N Engl J Med.2018;379(2):150-161. 34. Weller M,Cloughesy T,Perry JR,Wick W.Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol.2013;15(1):4-27. 35. Mandel JJ,Cachia D,Liu Dら,Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.J Neurooncol.2016;129(1):147-154. 36. Tabei Y, Kobayashi K, Saito K et al., Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status. Jpn J Clin Oncol. 2020 Sep 5; doi:10.1093 / jjco / hyaa162; online ahead of print.
Table 2
Claims
1. 1. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of a tumor of the nervous system in a patient, the patient having a mutated isocitrate dehydrogenase 1 (IDH1) gene, the pharmaceutical composition comprising perillyl alcohol (POH) or perillyl alcohol carbamate, the perillyl alcohol carbamate being perillyl alcohol covalently attached to a therapeutic agent via a carbamate linking group.
2. The use described in claim 1, wherein the tumor of the nervous system is glioblastoma.
3. The use of claim 2, wherein the glioblastoma is recurrent glioblastoma.
4. The use of claim 1, wherein the therapeutic substance is a chemotherapeutic agent.
5. The use of claim 4, wherein the chemotherapeutic agent is selected from the group consisting of DNA alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducers, platinum compounds, metabolic antagonists, enzyme inhibitors, receptor antagonists, therapeutic antibodies and combinations thereof.
6. The use of claim 4, wherein the chemotherapeutic agent is dimethyl-celecoxib (DMC), irinotecan (CPT-11), temozolomide or rolipram.
7. The use of claim 1, wherein the pharmaceutical composition is administered by inhalation, intranasal, oral, intravenous, subcutaneous or intramuscular administration.
8. The use of claim 1, wherein the pharmaceutical composition is administered using a nasal delivery device.
9. The use of claim 8, wherein the nasal delivery device is selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an injector, a unit dose container, a pump, a dropper, a squeeze bottle or a two-way device.
10. The use of claim 1, wherein the pharmaceutical composition is administered before, during, or after radiation exposure.
11. The use of claim 1, wherein the pharmaceutical composition is administered before, during, or after administration of a chemotherapeutic agent.
12. The use of claim 1, wherein the perillyl alcohol carbamate is selected from the group consisting of perillyl alcohol conjugated to dimethylcelecoxib, temozolomide POH carbamate (3-methyl 4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl)-carbamic acid-4-isopropenylcyclohex-1-enylmethyl ester) and rolipram POH carbamate (4-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxo)-pyrrolidine-1-carboxylic acid 4-isopropenylcyclohex-1-enylmethyl ester) or a mixture thereof.
13. 2. The use according to claim 1, wherein the (S)-perillyl alcohol has a purity of more than 99.0% (w / w) or a purity of more than 99.5% (w / w).
14. 14. The use according to claim 13, wherein the (S)-perillyl alcohol has a purity of more than 99.0% (w / w).
15. 14. The use according to claim 13, wherein the (S)-perillyl alcohol has a purity of more than 99.5% (w / w).
